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ABSTRACT
Purinergic receptors respond to extracellular nucleotides and their metabolites.
They act as important signaling transduction molecules in a variety of biological
processes and are important in a number of pathophysiologic conditions that impact
human health. A subset of these receptors acts as non-selective cation channels,
designated as P2X receptors, which can induce electrical activities in the cellular
membrane and thus impact cellular function. A number of longitudinal studies following
surgically or genetically induced heart failure animals have demonstrated potential
improvement of cardiac function with P2X4 receptor overexpression. We explore here
how P2X signaling affects cardiomyocyte excitability and leads to changes in
contraction in both computational and experimental models. We confirm computational
predictions of P2X induced membrane depolarization and subsequent changes in a
number of cardiomyocyte currents using whole cell patch clamp techniques. Direct
sodium cxxxentry via P2X channels leading to intracellular ion concentration changes
were detected with an increase in Na+-K+ ATPase peak current and enhancement of the
calcium entry mode of the Na+-Ca2+ exchanger. The latter we show may play a role in
the enhancement of contractile response by extracellular ATP. With the aid of
computational prediction and interpretation, our findings highlight the value of dynamic
considerations of channel currents and offer explanations for prior inconsistencies in the
purinergic field. Moreover, we establish an interaction between the P2X4 receptor and
nitric oxide production that may underlie its cardioprotective effects after myocardial
injury. This improved understanding of P2X action on the heart helps to improve our
evaluation of its targeting in clinical applications.
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Chapter 1
Introduction

a

The human heart is an amazingly efficient biological pump. It can adjust to a wide range
of situations, providing blood flow to our bodies while we rest or exercise strenuously; and it
works relentlessly, beating more than 2.5 billion times during an average lifetime. Diseases
associated with this marvelous organ, however, remain the leading cause of death in the United
States and are increasingly plaguing other developed and developing nations. The latest data
suggest that 1 in every 4 deaths in the United States is attributable to heart disease and
cardiovascular deaths represented 30% of all global deaths in 2008.2, 3 More than half of these
are due to coronary heart disease. Significant medical advances have been made in both
interventional techniques and pharmacological treatments used to prevent major injuries to the
heart and fatalities, but many questions remain regarding the progression of cardiac remodeling
after injury. Heart failure, or the inability of the heart to pump enough blood and oxygen to
support other organs in the body, affects 5.1 million people in the US and costs the nation an
estimated $32 billion each year in the cost of health care services and lost productivity.4
Treatment options, especially those that have been shown to prolong life rather than simply
provide temporary symptom relief, remain limited.
In addition to treating the underlying pathology that led the heart to fail, heart failure is
predominantly managed pharmacologically through the use of beta-blockers, angiotensin II
receptors blockers, angiotensin converting enzyme inhibitors, diuretics, and in some cases,
blood vessel dilators, aldosterone receptor antagonists, and digoxin. Inotropic therapy
a

Part of this chapter, particular the information on summary of purinergic receptors have been published
previously: Yang R, Liang BT. “Cardiac P2X4 Receptors: Targets in Ischemia and Heart Failure?” Circ Res. 111:397401. 08/2012.
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(dobutamine, milrinone) may be used in end-stage disease to make the heart pump harder,
forcing the heart muscle to contract more forcefully, and often also speeding up the heart’s
rhythm. These therapeutics can relieve and control symptoms, but the risk of death rises if they
are taken long term. Mechanical support in the form of a left ventricular assist device and
ultimately heart transplant are last resort options.
Many of the aforementioned pharmacological compounds have been developed based
on structural and functional insights from biologically active molecules that regulate heart
function. Extracellular application of adenosine triphosphate (ATP) and its derivatives has been
recognized to modify heart function for some time, with the first paper describing the effects of
adenosine monophosphate (AMP) and adenosine published in 1929.5 Since then, molecular
cloning has been used to identify a number of cellular receptors that respond to these
extracellular nucleotides, which are collectively referred to as purinergic receptors, and there
has been a rapid expansion of the purinergic field. Within the purinergic receptor family, the
ligand gated P2X4 non-selective cation channel was previously identified as an important
mediator of ATP’s effects in the endogenous murine heart. More interestingly, when mice with
cardiac specific overexpression of this receptor were subjected to different models of heart
injury/failure, they had better survival and preserved heart function. With this result in mind, in
this thesis, we undertake a number of studies to derive mechanistic insight into how activation of
this purinergic receptor impacts cardiomyocyte electrophysiology and contraction and how its
downstream signaling affects heart function. We begin with a review of the electrical activities of
the heart and excitation contraction coupling that serve as the basis of cardiac function and for
understanding how purinergic ion channels can impact heart function.

2

1.1 The cardiac action potential and its conduction
In order to maintain rhythmic contractions throughout one’s life, the heart relies on an
elegant electromechanically coupled system. Action potentials (APs), which coordinate
contractions from muscles that pump blood to the rest of the body, are generated by defined ion
fluxes through specific channels on the cardiomyocyte sarcolemma. The sinoatrial (SA) node
residing in the right atrium of the heart is typically the dominant pacemaker, containing
pacemaking cells capable of rhythmic spontaneous depolarizations. Their APs are distinct in
that they contain an ionic flux known as the pacemaker current, or the “funny current” (If) (also
described as Na+ (f), Figure 1.1A). If passes through a channel distinct from the fast sodium
channel responsible for rapid depolarization in ventricular muscle cells. Rather, the pacemaker
channel is activated by hyperpolarization and is thus open during repolarization of the cell, as
the membrane potential approaches its most negative values. The inward flow of Na+ ions
through the pacemaker channel then causes the membrane potential to become progressively
less negative during repolarization and eventually, depolarizes the cell to its threshold voltage.
The fast depolarization phase of the pacemaker cell AP is thought to rely mainly on Ca2+ influx,
as the persistently less negative membrane voltage of pacemakers keep the fast sodium
channels in these cells mainly inactivated. Repolarization relies on inactivation of the calcium
channels and increased activation of potassium channels leading to K+ efflux from cells (Figure
1.1A).

3

B

A

Figure 1.1 Cardiac Action Potentials
Action potentials from the SA node (A) and ventricular myocytes (B) with corresponding ion
permeabilities. The funny current If, or Na+ (f), gradually depolarizes SA pacemakers to
reach threshold for opening of Ca2+ channels that are responsible for the AP upshoot. In
ventricular myocytes, the membrane potential is stable until the depolarizing stimulus
arrives, which leads to opening of fast Na+ channels responsible for the rapid depolarization.
Repolarization is a balance of Ca2+ and K+ permeabilities. (Reproduced with permission
from http://www.nataliescasebook.com/tag/cardiac-action-potentials)

During depolarization, the electrical impulse spreads rapidly between cardiac myocytes
due to the presence of low-resistance connections known as gap junctions between neighboring
cells. First, atrial muscle fibers propagate the impulse from the SA node to the atrioventricular
(AV) node. Fibrous tissue surrounding the tricuspid and mitral valves ensures that there is no
direct electrical connection between the atrial and ventricular chambers other than through the
AV node. The speed of tissue depolarization and the conduction velocity along cells depend on
a number of factors, including the number of sodium channels, the magnitude of the resting
potential, and fiber arrangement. Specialized regions, such as Purkinje fibers, can contain more
densely arranged fiber and/or tissues with a high concentration of Na+ channels, which allow
electrical impulse to spread quickly within and between cells for rapid conduction. After
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traversing the AV node, the cardiac AP spreads into the rapidly conducting bundle of His and
Purkinje fibers, which then distribute the electrical impulses to the bulk of the ventricular muscle
cells. A visual summary is provided in Figure 1.2, which also demonstrates more detailed
differences in AP among different regions of the heart.

Figure 1.2 The Cardiac Conduction Pathway
The action potential is regularly initiated from the sinus node and propagated throughout the
heart via specialized tracks and by cell to cell communication. The typical sequence of action
potential travel and morphologies of different cell types found in each of the specialized regions
of the heart are shown. The summation of these electrical signals gives rise to the
electrocardiogram, which provides information about AP propagation. (Figure 6.7 from
Malmivuo J and Plonsey R. “Bioelectromagnetism: Principles and Applications of Bioelectric and
Biomagnetic Fields”. Reproduced with permission from Oxford University Press.)

The AP of the ventricular muscle cardiomyocytes is morphologically and ionically
different than that of the pacemaker cells (Figure 1.1B). The resting potential is typically more
negative than the pacemaker resting potential. When a depolarizing influence is encountered,
some sodium channels can open and the entry of Na+ ions into cells causes the transmembrane
potential to become progressively less negative. When the threshold potential is reached,
5

enough of these fast Na+ channels have opened to generate a self-sustaining inward Na+
current, resulting in a prominent influx of Na+ responsible for the rapid upstroke of the AP. The
fast sodium channels then undergo rapid inactivation while transiently activated potassium
channels are quickly activated by the large depolarization, which returns the membrane
potential towards negative values. The plateau phase of the muscle AP is mediated by the
balance of an outward K+ current in competition with an inward Ca2+ current though the L-type
calcium channels. These channels have a slower activation profile and remain open much
longer compared with fast sodium channels. Calcium ions that enter the cell during this plateau
phase are crucial in triggering additional internal calcium release from the sarcoplasmic
reticulum for initiating myocyte contraction. Repolarization of the AP occurs with continued
outward flow of K+ while Ca2+ channels gradually inactivate.

1.2 Sarcolemmal ion channels and currents in the cardiomyocyte
As previously mentioned, Na+ and Ca2+ influx are responsible for membrane
depolarization and a number of K+ channels are responsible for repolarization. The voltage
gated Na+ and K+ channels all consist of a primary α- and multiple secondary β-subunits. The αsubunit is responsible for passing current while the β-subunits modify channel expression levels
and regulate gating and channel kinetics. In contrast, the calcium channel is a combination of as
many as 5 subunits, α1, α2, β, γ, and δ. A list of these currents, with their respective proteins for
the primary α-subunits along with the encoding genes is included in Table 1.1. In addition to
these voltage sensitive channel currents, a number of transporters act to return Na+ and Ca2+
ions that enter the cell during depolarization to the extracellular environment and to bring K+
back into the cell. Ca2+ ions are removed by the Na+-Ca2+ exchanger (NCX) and to a lesser
extent by the plasma membrane Ca2+ ATPase pump (PMCA), while the Na+/K+-ATPase pump
makes the corrective exchange of Na+ and K+. All three of these transporters are electrogenic,
capable of generating currents that influence the AP and resting potential.
6

Current

Description

Activation
mechanism
α-subunit of inward current channels
INa
Sodium current
Voltage,
depolarization
ICa,L
Calcium current,
Voltage,
L-type
depolarization
ICa,T
Calcium current,
Voltage,
T-type
depolarization
α-subunit of outward (K+) current channels
Ito,f
Transient
Voltage,
outward current,
depolarization
fast
Ito,s
Transient
Voltage,
outward current,
depolarization
slow
IKur
Delayed rectifier, Voltage,
ultrarapid
depolarization
IKr
Delayed rectifier, Voltage,
fast
depolarization
IKs
Delayed rectifier, Voltage,
slow
depolarization
IK1
Inward rectifier
Voltage,
depolarization
Specialized Outward Current
If
Pacemaker
Voltage,
current
hyperpolarization

Clone

Gene

Nav1.5

SCN5A

Cav1.2

CACNA1C

Cav3.1/
Cav3.2

CACNA1G

KV4.2/4.3

KCNF2/3

KV1.4/1.7/3.
4

KCNA4/7, KCNC4

KV1.5/3.1

KCNA5/KCNC1

HERG

KCNH2

KVLQT1

KCNQ1

Kir 2.1/2.2

KCNJ2/12

HCN2/4

HCN2/4

Table 1.1 Membrane Currents that underlie the Action Potential
Modified with permission from Grant AO, “Cardiac Ion Channels”. Circulation: Arrhythmia and
Electrophysiology 2009.6

1.3 From Excitation to Contraction
In response to APs generated by sarcolemmal ionic currents, cardiomyocytes contract
by cycling calcium between the sarcoplasmic reticulum (SR) and the cytoplasm. Activation of Ltype Ca2+ channels results in a small influx of Ca2+ ions into the cell that is insufficient to cause
contraction, but triggers a greater Ca2+ release from the SR, known as Ca2+ induced Ca2+
release (CICR). The T-tubule invaginations of the sarcolemmal membrane bring the L-type
channels into close apposition with ryanodine receptors (RyRs) on the SR, which undergo a
conformational change in response to the L-type channel Ca2+ influx to allow a much greater
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release of Ca2+ from the SR. A single L-type calcium channel can trigger SR Ca2+ release only
from a locally apposed cluster of RyRs, and statistical recruitment of release clusters brings
about graded release,7 in which the Ca2+ released from the SR is graded according to the
amount of trigger Ca2+ entering the cell via L-type Ca2+ channels.8
The sensitivity of troponin C to Ca2+ is the crucial link from Ca2+ transients to mechanical
activity. Troponin is composed of three subunits; in addition to troponin C that binds Ca2+,
troponin T links the troponin complex to actin and tropomyosin molecules, and troponin I inhibits
the ATPase activity of the actin-myosin interaction that leads to crossbridge formation. Actin
and myosin are the chief force generating molecules in contraction. Myosin molecules are
arranged in thick filaments, which are tethered by titin to the z-lines of sarcomeres. Actin is
arranged in thin filaments as an α-helix of two strands that interdigitate between the thick
myosin filaments. Under resting conditions, tropomyosin lies in the grooves between the actin
filaments and inhibits the interaction between myosin heads and actin, preventing contraction.
Ca2+ binding to tryponin leads to conformational change in tropomyosin, exposing active sites
between actin and myosin filaments, allowing crossbridge formation and for the filaments to
slide across each other. As long as the cytosolic Ca2+ concentration remains sufficiently high to
inhibit the troponin-tropomyosin blocking action of crossbridge formation between actin and
myosin, progressive ATP-dependent reactions between the myosin head and actin causes the
muscle fiber to shorten by increasing the overlap between the myofilaments within each
sarcomere. Relaxation occurs when Ca2+ is removed from the cytosolic space, largely through
sequestration back into the SR by the sarcoendoplasmic reticulum Ca2+ ATPase (SERCA)
pump, while a smaller fraction is extruded into the extracellular space by the NCX and the
PMCA.

8

1.4 Computational Models of Cardiac Electrophysiology and Contraction
The generation of the AP followed by excitation-contraction coupling is a highly dynamic
process with a carefully timed sequence of events that occur on the millisecond scale. To
understand these complex interactions, quantitative modeling has been utilized to analyze each
process, and is exemplified by the original Hodgkin-Huxley description of the squid giant axon
AP, which has been the standard for describing voltage-dependent membrane ion current
dynamics for over 60 years.9 This model introduced the concept of channel gating, and related
currents through ensembles of channels to the state of these gates. The first computational
model of a cardiac myocyte, the Purkinje cell, was developed based on the Hodgkin-Huxley
formalism and was presented by Denis Noble in the early 1960s.10 Early models explored
mechanisms underlying the long AP duration observed in cardiac myocytes compared to
neurons, which was explained as a balance between a maintained inward Na+ current and a
slowly activating outward K+ current. Relative Na+ and K+ conductances could be adjusted to
produce a stable resting potential or a stable oscillation that mimicked the oscillatory long
duration APs of the cardiac Purkinje fiber. While we now know that the inward current during the
plateau phase of the cardiac AP is primarily due to membrane Ca2+ permeability and that the
conclusions of the earliest models were inaccurate, they were nonetheless fundamentally
important in trying to achieve detailed mechanistic and quantitative understanding of the
cardiomyocyte AP. Subsequent elaborations led to the development of the 1985 DiFrancescoNoble model 11, which has become a template for pacemaking cell models. In addition to
including hyperpolarization activated If conductance for pacemaking in the Purkinje fiber, it also
incorporated time-varying concentration of ions in the cell, activities of the Na+/K+ ATPase and
NCX, and voltage and calcium dependent inactivation of the calcium current. It also introduced
components of subcellular Ca2+ movement, where Ca2+ is taken into the SR by SERCA and can
diffuse from the nonjunctional SR (NSR) to the junctional SR (JSR) for CICR from the JSR. All
subsequent models of the cardiomyocyte have been built based on this framework.
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The first ventricular cell model based on voltage clamp recordings obtained from isolated
myocytes was reported in 1991.12 This first Luo and Rudy model based on data from guinea pig
ventricular myocytes described six distinct membrane currents and substantially progressed the
field, as current descriptions were carefully based on existing experimental data and model
equations were fully published to enable implementation by other investigators. Their second
model published in 1994 included sarcolemmal pumps and exchangers, intracellular Ca2+
buffers, CICR and Ca2+ cycling. The development of quantitative models greatly benefited from
technical advances in the spatiotemporal control of single cell voltage clamping, which allowed
for increasingly sophisticated experiments to generate more detailed data and even leading to
single channel measurements. Concurrent with these new technical advances, subsequent
models have become increasingly biophysically detailed. Markov chain models are now
commonly used to describe gating behavior, and are comprised of a number of different states
that loosely correspond to different conformations of channel proteins as they undergo
activation and inactivation, with transition rates between certain states being voltage-dependent.
The Markov property of “memorylessness” assures that the future evolution of the process state
depends only on the current state and overcomes the limiting assumption of Hodgkin-Huxley
that channel gates behave independently. More detailed descriptions of CICR mechanisms
represent another area of advance in the modern model of the cardiac myocyte. Statistical
recruitment of calcium release units underlying graded calcium release can be modeled by
including a population of dyadic Ca2+ release units in which local interactions of individual
sarcolemmal L-type calcium channels and nearby RyR are simulated stochastically13. As the
computational resources involved in such modeling can be overwhelming, simplified local
control models of CICR are often formulated by applying a carefully chosen set of
approximations that allow for the ensemble behavior of Ca2+ release units to be represented by
simple ordinary differential equations14. These important modeling features are included in the
Bondarenko model15 (Figure 1.3), which was parameterized to fit experimental observations
10
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Figure 1.3 Excitation-Contraction Coupling as presented in an Integrated
Cardiomyocyte Model
(A) Major membrane ionic currents that give rise to the AP are shown, with L-type calcium
channel current ICaL coupled to calcium release from the junctional SR. Rising cytosolic Ca2+
can bind to tryponin, leading to myofilament overlap that generates contraction. Depolarizing
currents INa and ICaL, repolarizing K+ currents IKto,f, IKto,s, IKs, IKr, IKur, IKss, IK1, transporter and
pump currents INaK, INaCa, Ip(Ca), background currents INab, ICab, and a calcium activated chloride
current ICl,Ca were included in this model of the murine ventricular myocyte. Markov
descriptions of gating mechanisms were implemented for INa, ICa,L, and IKur. (B) Sequence of
AP initiation to force generation for a representative cardiac beat. (C) Dynamics of underlying
currents for a typical AP. Top panel illustrates a typical mouse AP as outputted by the
computational model. Middle panel demonstrates the large currents shaping the AP, note the
axis for INa is on the right. By convention, inward positive ion movement constitutes a negative
current. Notice the rapid time course for INa and the balance between ICa,L and outward going
K+ currents during the repolarization phase. Bottom panel shows smaller magnitude ion
movements that are active both during AP firing and at rest. (Figures reproduced with
permission from Bondarenko et al, 2004 and Mullins et al, 2013.15, 16 )
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from murine myocytes. Since our experiments are based in mice, which are amendable to
genetic modification and experimental manipulation, this mouse ventricular myocyte model
serves as the basis of further computational modifications and study in this thesis as well.

1.4.1

Comparison of the Mouse vs. Human action potential
While the fundamental mechanism of excitation contraction coupling is similar in the

mouse compared to the human heart, a number of differences are worth noting. In the mouse
heart, the L-type Ca2+ current contributes less to the ventricular AP than in humans, and
therefore the murine AP shows a gradual repolarization rather than a distinct plateau phase. In
humans, the plateau phase ends when the balance shifts from the slowly inactivating ICa,L to
slowly activating potassium currents, giving rise to the final repolarization until the resting
potential is restored. In human ventricular myocytes, Ito,f is mainly involved in the first phase of
repolarization and IKr and IKs are predominantly responsible for the late repolarization, whereas
the much faster repolarization in murine ventricles is mediated by Ito,f, Ito,s, IKs, and a noninactivating steady state K+ current (IKss). The equivalent of the murine IKss has not been
detected in human ventricles.17 Ca2+ handling is somewhat different in mice, where up to 90% of
Ca2+ is taken back up into the SR.18, 19 In larger mammals, approximately 70% of Ca2+ is taken
back into the SR and 30% is eliminated by the NCX and PMCA. Murine myocytes also have a
higher cytoplasmic Na+ concentration than larger mammals, which favors less extrusion of Ca2+
by the NCX, consistent with a higher fraction of SR Ca2+ reuptake.20 While an increase in heart
rate often leads to enhanced SR Ca2+ loading by decreasing the diastolic period for calcium
extrusion, leading to greater contractile force at higher heart rates in larger mammals, the lower
fraction of NCX-mediated Ca2+ extrusion in mice could explain why an increase in heart rate
hardly affects SR Ca2+ load in mice. Combined with refractoriness of excitation contraction
coupling, in which reduced fractional SR calcium release occurs at higher frequencies, a
negative force-frequency relationship prevails in the mouse.20 While important differences exist
12

between the mouse and larger mammals, transgenic mouse models are still a valuable tool for
preclinical studies and results should be interpreted with these differences in mind.

1.5 Overview of Purinergic Receptors
Purinergic receptors were initially conceived to describe the likely existence of
membrane receptors responding to ATP (P2 receptors) or its breakdown product adenosine (P1
receptors) in causing non-adrenergic, non-cholinergic relaxation of gut smooth muscle.21
Cloning of these receptors has yielded insights into their properties and signaling mechanisms,
allowing further P2 classification into sub-families of seven ionotropic (P2X) and eight
metabotropic (P2Y) receptors based on structure.22 P2X channels respond to ATP as their only
endogenous ligand and are organized as homo- or hetero-trimers of two transmembrane
domain subunits that form non-selective cation channels, though some channels have been
demonstrated to allow passage of anions and large molecules.23 The P2Y receptors are Gprotein coupled receptors that have recently been shown to form hetero-oligomers as well.24 In
addition to endogenous ATP and ADP, P2Y receptors respond to the pyrimidines UTP and UDP.
P2Y1, P2Y2, P2Y4, and P2Y6 are coupled to Gq to activate PLCβ, leading to IP3-mediated
mobilization of intracellular calcium storage, while P2Y12, P2Y13, and P2Y14 couple to Gi and
thus inhibit adenylyl cyclase. P2Y11 uniquely couples to both Gq and Gs to increase calcium and
cAMP (summarized in Figure 1.4).
Purinergic receptors are now associated with a number of important roles in normal and
patho-physiology25. Adenosine has been employed extensively as a vasodilator and an antiarrhythmic, and efforts to target each adenosine receptor subtype as novel therapies are
ongoing.26 P2Y12 antagonists are also utilized as cardiovascular therapies27 and
pharmacological interest exists for a number of other P2 receptors for a wide range of clinical
applications,28, 29 with the P2X class most notably targeted for chronic pain treatment and
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immunomodulation.30 Here we focus our attention on P2 receptors in the heart, and more
specifically on novel aspects of the P2X4 receptor.

Figure 1.4 Summary of Purinergic Signaling.
Three broad categories of receptors respond to extracellular purines and pyrimidines. P2X
refers to nonselective cation channels that respond to ATP, with some subtypes
demonstrating the ability to pass anions and large molecules. P2Y receptors are G-protein
coupled receptors that respond to endogenous ATP and ADP, as well as the pyrimidines
UTP and UDP. Activation of P2Y1, P2Y2, P2Y4, and P2Y6 lead to Gq coupled PLCβ
signaling, leading to IP3-mediated mobilization of intracellular calcium storage. P2Y12,
P2Y13, and P2Y14 couple to Gi and thus inhibit adenylyl cyclase. P2Y11 is uniquely coupled
to both Gq and Gs and can increase calcium and cAMP. Further breakdown of ADP to
AMP and adenosine can then lead to activation of adenosine receptors (also referred to
as P1 receptors or A receptors), which are also G-protein couple receptors. Three
subtypes have been identified, with A1 and A3 stimulating Gs while A2 is coupled to Gi.
1.6 P2 receptors in the heart
Studies of ATP’s effects on the heart predate the conception of purinergic receptors.
While extracellular ATP concentration is typically in the nanomolar range, ischemic events can
cause an increase up to hundreds of micromolars,31 leading to the activation of the myriad of
receptors described in Figure 1.4. Some of the earliest studies of extracellular ATP application
were motivated by its large increase in injury/trauma,32, 33 though it wasn’t realized until later that
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the cardiac muscle cells can also release ATP in response to hypoxia.34 Many of the early
identified effects on the heart have been shown to be mediated by adenosine due to the fast
breakdown of ATP to adenosine by extracellular ectonucleotidases.35 Adenosine is thought to
be the main active compound responsible for the negative chronotropic, heart block, and
vasodilatory effects seen with ATP administration, which is the basis for utilizing ATP bolus
injections as an anti-arrhythmic to terminate supraventricular tachycardia.36, 37 Additionally,
adenine nucleotides given to isolated perfused mammalian hearts often caused a positive
inotropic effect, in many cases shown to be exerted directly on the myocardium rather than
through the vasodilatory effects of these compounds.38 Increasing the phosphorylation status of
adenosine (ATP> ADP> AMP) correlated well with an increasing effect on cardiac contractility,
whereas adenosine itself had no direct effect on cardiac contractility,38 suggesting P2 receptor
mediated contractile enhancement. This effect has also been described in the human
myocardium.39 However, as the rate of degradation of these compounds in vivo is difficult to
control and the large number of possible receptors lead to combinatorial complexity that is
difficult to unravel, the effects of ATP on the heart and the mechanisms leading to them are still

Reference
Banfi C, et
al. 2005

Species Cardiac Disease
region
Human
LV
CHF &
healthy

Receptors present

All at the mRNA level.
Protein not confirmed for P2X5 & P2Y2
P2X6 upregulated in CHF
Musa H, et Human
RA and Healthy
mRNA for P2X4-7 and P2Y1,2,4,6,12-14
al. 2009
SAN
P2X: P2X4, 7 most abundant
P2Y: P2Y1, 2 most abundant in RA,
P2Y1, 2, 14 most abundant in SAN
Rat
LV, RA, Healthy
Healthy
and
vs.
P2X: P2X5 most abundant in all regions
SAN
Coronary P2Y: P2Y1, 12, 14 most abundant in LV
artery
P2Y2,13 highest in RA & SAN
ligation
Coronary artery ligation
P2X4 mRNA upregulated by 93% in the
SAN, non-significant increase trend in the
RA & LV
Table 1.2 Widespread P2 receptor expression in cardiac tissue.
Note regional and species differences. CHF= Congestive heart failure, LV = left ventricle, RA =
right atrium, SAN = sinoatrial node.
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debated. It is worth noting that transcripts for all P2 subtypes have been detected in the hearts
of human and rodent,40, 41 and additional changes and regulations can occur during
pathological conditions (Table 1.2). Overall, a better understanding of the role of cardiac P2
receptors and their regulation in diseased hearts is likely to have implications for preventing
and slowing the progression of disease.
In isolated cardiac cells, early experiments in adult rat myocytes showed that
extracellular ATP evoked a transient increase in intracellular Ca2+ concentration in quiescent
cells, and that extracellular Ca2+ influx was necessary for this change.42-45 ATP stimulated the
trans-sarcolemmal influx of Ca2+, whereas ADP, AMP and adenosine were ineffective.38, 45. This
was associated with an ATP-activated inward current that had a reversal potential near 0mV,
suggesting the presence of ATP-gated cation channels in the cardiomyocyte, and was further
accompanied by depolarization towards the threshold of AP firing in rat myocytes.45 Under
quiescent conditions, oscillatory contractions could be induced, in which the frequency but not
the amplitude was regulated by the concentration of extracellular ATP.46 Ca2+ release and
uptake by the SR was necessary for the observed oscillations in intracellular Ca2+ concentration
and contraction. During electrical stimulation, extracellular ATP activation of purinergic receptors
was shown to both potentiate the amplitude of electrically stimulated contractions and induce
spontaneous contractions.42, 46
The extracellular ATP induced inward current has been replicated in various species.44, 47,
48

In adult ventricular myocytes from healthy wild type mice, P2 agonism caused an increase in

a non-selective cation current.49 An analogue of ATP with a methylthio group in place of
hydrogen in position 2 of the adenine nucleobase: 2-methylthioadenosine-5'-o-triphosphate (2meSATP), was used for its higher resistance to nucleotidase breakdown and its inability to
activate P2Y receptors (thought at that time) and coronary vasodilatory (adenosine) effects 50 to
limit the impact of confounding factors on the heart. The reversal potential of this current was
similar to that of the cloned P2X4 receptor.47 Furthermore, the current induced by 2-meSATP
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was partially insensitive to antagonism by suramin and pyridoxalphosphate-6-azophenyl-2′,4′disulphonic acid (PPADS), which is also a characteristic of the P2X4 receptor.47, 49 The P2X4
receptor, structurally similar to others in the P2X family, have EC50 for ATP similar to P2X2,5,6,
higher than P2X1,3, and approximately one order of magnitude lower than P2X7. Its unique
property of being potentiated by ivermectin also allows for its identification.

1.7 Cardiac specific manipulation of the P2X4 gene in mice
A reductionist approach led to identification of the P2X4 channel as a likely important
endogenous component of the cardiac response to P2 agonism. To further understand the
effects of this channel, a cardiac specific overexpression mouse model was created by
subcloning the human P2X4 cDNA into an expression vector carrying the alpha myosin heavy
chain (α-MHC) promoter, which confers cardiac specific expression.51 After sequence
verification, the recombinant clone was purified and microinjected into the male pronucleus of
the B6SJL/F1 mouse zygote, which was then implanted in pseudopregnant female mice.
Founders and subsequent generations of transgenic mice were identified by PCR and
immunoblotting for protein expression. Immunoblotting suggested an average of 20 fold
overexpression over wildtype while electrophysiological data demonstrated an approximate
doubling of inward current with 3µM of 2-meSATP treatment.47
2-meSATP induced a greater increase of contractility in cardiac myocytes isolated from
these transgenic mice than in wild type myocytes,51 further indicating that the P2X4 receptor has
a physiological effect in native murine myocytes and that the signal can be augmented with
transgenic overexpression. Under basal control conditions, these mice with cardiac speciﬁc
P2X4 receptor overexpression (P2X4ROE) were overtly normal without cardiac hypertrophy or
failure as they age.51 Their response to cardiac injury, however, proved more interesting. These
mice were shown to be protected from a genetic model of calsequestrin (CSQ) overexpression-
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induced heart failure (HF),52, 53 in which CSQ binds to Ca2+ in the SR and impairs its release
during cardiac cycles. The expression of the cardiac P2X4 receptor was increased in the CSQ
overexpressing model of hypertrophy and dilated cardiomyopathy, and the 2-meSATPstimulated current was also greater in ventricular myocytes isolated from the CSQ mice as
compared to WT mice. This indicated a possible role for the P2X4 receptor in pathophysiology
but also suggested a potentially compensatory mechanism, as P2X4R OE/CSQ OE double
transgenic mice had improved survival and cardiac function.52 Moreover, in the more disease
relevant model of left anterior descending coronary artery ligation to induce ischemia and
consequent HF, the P2X4R OE mice showed improved survival and better preserved cardiac
function as compared to WT (Figure 1.5 and Table 1.3).1 P2X4R expression, as assessed by
immunoblotting for protein, did not change in the remote non-infarcted region in post-infarct WT
mouse hearts, though it has been shown to be up-regulated in the right ventricles of rats
exposed to hypobaric hypoxia.54 The downstream mechanism(s) by which this ATP-gated nonselective cation channel protects against myocardial functional deterioration is still incompletely
understood, but the inotropic support offered by P2X activation may supply the needed
functional enhancement during the critical period after ischemic injury.1

Figure 1.5 Improved Survival in P2X4R overexpression mice after ischemia injury
P2X4 receptor overexpression transgenic (P2X4R Tg) mice demonstrated less mortality
after myocardial infarction (MI) induced by left anterior descending coronary artery ligation
in both (A) females and (B) males. Gender differences are consistent with known improved
outcome in females. (Figure reproduced with permission from Sonin, et al. 2008.1)
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Table 1.3 Echocardiographic parameters in WT and P2X4ROE animals after Ischemic Injury
Females
Time After MI
7 days
WT
P2X4R OE
1 month
WT
P2X4R OE
2 months
WT
P2X4R OE

N

FS, %

LVPW Thickening, mm

LVEDD, mm

LVESD, mm

MI Size, %

28
21

20.50±0.59†
22.60±0.84*

0.059±0.0047†
0.079±0.0100*

3.87±0.0840†
3.91±0.0970†

3.08±0.0770†
3.05±0.0850†

40.4±4.02†
38.3±3.37

19
14

18.80±0.59
24.20±0.77*

0.053±0.0055
0.080±0.0100*

3.91±0.1100
4.19±0.1350

3.18±0.0950
3.19±0.1220

43.2±2.90
40.5±3.14

22
17

18.49±0.56
23.14±0.76*

0.040±0.0052
0.102±0.0140*

4.27±0.1600
4.39±0.1590

3.51±0.1430
3.39±0.1370

27.0±2.03
30.5±3.20

N

FS, %

Males
19

Time After MI

LVPW Thickening, mm

LVEDD, mm

LVESD, mm

MI Size, %

7 days
WT
28
17.65±0.49
0.051±0.0047
4.34±0.0870
3.53±0.10
44.8±3.67†
P2X4R Tg
21
24.50±0.95*†
0.090±0.0083*
3.98±0.1600*
3.14±0.13*
38.1±4.22
1 month
WT
14
18.23±0.85
0.035±0.0056
4.33±0.1500
3.57±0.14
44.0±1.92
P2X4R Tg
10
22.72±1.14*
0.090±0.0160*
4.57±0.2190
3.55±0.21
42.3±1.83
2 months
WT
23
17.15±0.88
0.053±0.0055
4.29±0.1600
3.53±0.15
31.9±1.73
P2X4R Tg
18
20.42±0.98*
0.087±0.0096*
4.62±0.2900
3.68±0.26
33.6±4.90
Values are means ± SE. At 7 days, 1 month, and 2 months after LAD ligation-induced myocardial infarction, WT and P2X4R OE
mice of either sex were subjected to echocardiography evaluation of cardiac function. The various echocardiographic measurements
were obtained as shown. FS=fractional shortening, LVPW=left ventricular posterior wall, LVEDD=left ventricular end diastolic
dimension, LVESD=left ventricular end systolic dimension. MI size was determined by histology with Masson Trichrome
staining. *P < 0.05 vs. WT mice at the same time point after MI. †P < 0.05 vs. the 2-month time point. (Table reproduced with
permission from Sonin, et al. 2008.1)

Further characterization of the effects of 2-mesATP in P2X4ROE cardiac myocytes
showed that the enhanced myocyte contractile response was not accompanied by any
change in the L-type calcium channel current-voltage relationship. This observation, along
with the lack of depolarization in response to 2-meSATP (re-examined in Chapter 3),
indicated no Ca2+ influx via the L-type Ca2+ channel during P2X agonism.55 However,
increased SR calcium loading was seen in P2X4R OE transgenic myocytes with exposure to
agonist, providing a mechanism for P2X4 receptor-mediated increase in contractility and
suggesting that another source of Ca2+ may be involved. Among the P2X receptors, P2X4 is
one of the most Ca2+ permeable, though the majority of entering ions are still Na+. Enhanced
Na+ entry via overexpressed P2X4 channel may act to further increase Ca2+ by affecting the
NCX, which we further explore in the next chapter. Localized domains of Ca2+ increase at
the plasma membrane may activate Ca2+-dependent protein(s) in close vicinity of the
receptor channel, after which diffusion of Ca2+ may reach the SR to enhance its loading.
Endothelial nitric oxide synthase (eNOS) is one possible interacting protein activated
by Ca2+ and calmodulin. Studies on a global P2X4R knockout mouse model have
demonstrated that this receptor is an important mechano-transducer in endothelial cells, with
P2X4R knockout endothelial cells exhibiting abnormal shear responses. This was
demonstrated to be due to a lack of force-induced Ca2+ influx and subsequent nitric oxide
production.56 This role in maintaining flow-induced vasodilation is important in physiological
vascular homeostasis, as a single nucleotide polymorphism leading to decreased ATP
binding was recently associated with increased pulse pressure in humans.57 No cardiac
performance observation has been mentioned about the P2X4R knockouts, presumably due
to a lack of significant basal phenotype change, though it would be of interest to see if
exposing these animals to cardiac insult exposes a diseased phenotype. Given a possible
link between P2X4 receptors and eNOS, as well as the known cardioprotective effect of nitric
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oxide and cGMP-dependent protein kinase (PKG),58 it is intriguing to suspect a role for
eNOS in mediating an anti-hypertrophic effect, offering protection from ischemia injury and
development of heart failure in the P2X4R OE mice (Chapter 4).

1.8 Aims and Significance of this Research
By combining experiments with computational modeling, we sought to understand
the effect of the P2X4 channels on cardiac function in the integrated framework of excitation
contraction coupling. In light of previous work on this channel, which demonstrated inotropic
enhancement and protection in ischemic injury, a number of aims to assess the risks and
feasibility of targeting these receptors in the treatment of cardiac disease were developed
and the results are presented in the referred chapters.

AIM 1: To understand P2X impact on cardiomyocyte Na+ handling and its possible
involvement in contractile enhancement (Chapter 2)
We examine if Na+ influx via the P2X4 channel can modify activities of other important
transporters in cardiac myocytes, namely the Na+/K+-ATPase pump and the NCX. Increased
intracellular Na+ concentration can favor the Ca2+ entry mode of the NCX, whereby Na+ is
pumped out in exchange for Ca2+ entry, thus enhancing the calcium transient and
contraction. We quantify the level of intracellular Na+ concentration change in response to
purinergic activation and test whether the NCX may be involved in P2X-elicited
enhancement of contraction.

AIM 2: To test cardiomocyte and whole heart excitability following P2 agonism
(Chapter 3)
The flow of positive charge into the cell can induce depolarization, which in the
context of a cardiomyocyte can alter AP generation and its propagation in the whole heart.
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ATP has been suggested in some studies to cause spontaneous electrical activities and
arrhythmias, though the mechanism is not entirely understood. We take advantage of our
P2X4R overexpressing hearts to test whether cellular excitability and whole heart ectopic
activity is increased with activation of these channels.

AIM 3: To examine if nitric oxide signaling is activated following P2 agonism and
whether it has a role in P2X4R-mediated protection (Chapter 4)
Nitric oxide signaling, particularly through eNOS, is one of the calcium dependent
pathways known to be protective against injury and heart failure. P2X4 receptor dependent
eNOS activation has been suggested in vascular endothelial cells. We test if there is an
interaction between P2X4R and eNOS in the cardiomyocyte and if this mediates P2X4R
overexpression conferred cardioprotection.

The research presented here makes significant contributions to understanding how
purinergic channels can affect heart function. Genetically modified animals allow us to
further dissect mechanisms underlying ATP-mediated effects, which remain largely elusive
due to challenges in pharmacology. We build upon findings from the cardiac specific P2X4R
overexpression mouse and utilize additional genetic and pharmacological tools to derive new
insight into the mechanisms that could underlie P2X4R overexpression mediated protection.
Furthermore, with the computational framework of the cardiomyocyte in mind, we consider
the dynamics of the P2X current in re-evaluating prior controversies in the field on ATPinduced arrhythmogenesis. Our results suggest that P2X receptors may be a viable target
for cardiac treatment with transient effects on excitability.
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Chapter 2
Cardiac P2X Purinergic Receptors as a New
Pathway for Increasing Na+ Entry in Cardiac
b
Myocytes
2. 1 INTRODUCTION
Intracellular Na+ concentration and its homeostasis are important in regulating the
contractile and electrical activity of the heart.59 The sarcolemmal Na+-K+ ATPase (Na+ pump)
utilizes energy derived from the hydrolysis of ATP to generate an outward pump current
carried by Na+ at rest as well as during action potentials to maintain resting potential.60 The
Na+/Ca2+ exchanger (NCX) is a major mechanism of Ca2+ extrusion in the cardiomyocyte, but
through its Ca2+ entry mode can also extrude Na+ from the cardiac myocytes.61, 62 P2X
receptors are ligand-gated ion channels which are permeable to Na+, K+ and Ca2+ with a
reversal potential near 0 mV.63, 64 Extracellular ATP, a P2X receptor ligand, can induce a
nonselective cationic current in murine,47 rat,44 and guinea pig48 cardiac ventricular myocytes.
Under normal extracellular Ca2+ concentration (1.8mM), Ca2+ contributes about 8% of the
total inward current induced by ATP via homotrimeric human P2X4R expressed in HEK
cells.65 However, most of the ATP-induced inward current is carried by Na+.47, 65 To confirm
the functional importance of this Na+ entry pathway, we examined the effects of Na+ entry via
P2X receptors on the activities of either Na+-K+ ATPase or NCX as each is sensitive to
b

This chapter is adapted from a prior publication: Shen JB*, Yang R*, Pappano A, Liang BT. “Cardiac
P2X purinergic receptors as a new pathway for increasing Na+ entry in cardiac myocytes”. Am J
Physiol Heart Circ Physiol. 2014 Nov 15; 307 (10):H1469-77. *First 2 authors contributed equally.
J.B.S. and R.Y. performed experiments; J.B.S., R.Y., A.J.P., and B.T.L. analyzed data; R.Y. carried out
mathematical simulations; J.B.S. and R.Y. prepared figures and drafted manuscript; J.B.S., R.Y., A.J.P.,
and B.T.L. approved final version of manuscript; R.Y., A.J.P., and B.T.L. interpreted results of
experiments; A.J.P. and B.T.L. participated in conception and design of research; A.J.P. and B.T.L.
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intracellular Na+ changes. Myocyte contraction was also tested in the presence of Ca2+ entry
mode NCX inhibitors, KB-R 7943 and YM-244769, to determine the role of the NCX in 2meSATP-stimulated contraction. Studies were carried out in P2X4R overexpression cardiac
ventricular myocytes to facilitate detection of an effect on Na+-K+ ATPase and NCX activities
by P2X agonist. Current-voltage (I-V) relationships of the Na+ pump and NCX were also
simulated with mathematical modeling. Similar studies were carried out in ventricular
myocytes of wild type (WT) mice to explore the physiologic relevance of this receptor in
modulating Na+ handling.

2. 2 MATERIALS AND METHODS

2.2.1

Isolation of Adult Cardiac Myocytes
P2X4 receptor overexpression (P2X4R OE) mice were generated and bred as

previously described.51, 55, 66 Animals were maintained according to protocols approved by
the Institutional Animal Care and Use Committee at the University of Connecticut Health
Center and conform to the Guide for the Care and Use of Laboratory Animals from the
United States National Institutes of Health. Cardiac ventricular myocytes were obtained from
3-month-old cardiac specific P2X4R OE or WT mice of either sex using an enzymatic
dissociation procedure.47 Briefly, the heart was rapidly excised from mice that had been
adequately anesthetized using a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg).
Animals were also anti-coagulated with 1000 U of intra-peritoneal heparin. The aorta was
cannulated while visualized under a surgical microscope, then we perfused the heart on a
Langendorff apparatus at 37°C with a calcium-free oxygenated buffer containing (in mM):
125 NaCl, 4.4 KCl, 1 MgCl2, 4 HEPES, 18 NaHCO3, 11 glucose, 3 2,3-butanedione
monoxime, pH 7.3. After 2-3 min, the coronaries were free of blood, and the perfusion buffer
was switched to the same buffer containing 0.08mg/mL Liberase Blendzyme 4 (Roche
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Molecular Biochemicals) and 25µM CaCl2 for 10 min. The left ventricles were minced and
titurated to yield myocytes. Myocytes were then exposed ultimately to and kept at 1.0mM
external CaCl2 for studies. Myocytes that maintained a rod shape without blebs or blurred
striation in light microscopy were studied. For contraction studies, myocytes also needed to
meet the criteria of remaining quiescent without spontaneous contraction at baseline while
capable of generating contractions when electrically paced. The experiments were carried
out at room temperature (22 to 23°C) and were completed within 5 h after myocyte isolation.

2.2.2

Whole cell patch-clamp method
The whole cell patch-clamp technique was used for the experiments. Electrodes

were prepared from borosilicate glass pipette (1.2 mm i.d.) with a two-step pulling procedure
and filled with pipette solution (see below). Electrode resistances were 2–4 MΩ. The pipette
was connected via an Ag-AgCl wire to the head stage of an amplifier (List EPC-7, Medical
Systems, Greenvale, NY). After electrical contact was established for a few minutes,
membrane capacitance was calculated from a -5 mV voltage step. Voltage commands and
data acquisition were accomplished with Axon pClamp software version 9.0.

2.2.2.1 Na+/Ca2+ exchange current (INCX) measurement
To measure INCX, electrodes were filled with a solution containing (mM): 135 cesium
aspartate, 5 Na2ATP, 3 MgCl2, 10 HEPES, and 10 EGTA (pH 7.3 adjusted with CsOH). The
outlet of the rapid solution changing device (SF-77B, Warner Instrument) was brought within
50 µm of the cell. Then the superfusion medium was changed to a modified Tyrode’s
solution (5.4 mM KCl was omitted and 10 mM CsCl, 10 µM nifedipine and 5 µM ouabain
were added to Tyrode’s solution) to block K+ currents, L-type Ca2+ current (ICaL) and the Na+
pump current (Ip), respectively. The voltage protocol used to elicit INCX was as follows: from a
holding potential of -80mV, a brief 10ms step to +80mV was followed by a 2 s repolarizing
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ramp to -100mV. The ramp was applied to myocytes three times at one second intervals and
then the superfusing fluid was rapidly changed to a solution containing 10 mM NiCl2 for 10 s.
At the end of the Ni2+ application, the same ramp protocol was applied again. Three Ni2+sensitive current traces from 60 mV to -100 mV were averaged to construct the I-V
relationship of INCX under control conditions.67, 68 Then, 3 µM 2-meSATP was added to the
superfusion solution for 3-4 min while the myocyte was clamped at -80mV. The same
procedures of ramp protocol and rapid solution change were applied again in the presence
of 2-meSATP. The I-V relationship of INCX, taken as the Ni2+-sensitive current, was compared
in the absence and presence of 2-meSATP.
To measure only the Ca2+ entry mode of INCX, the current at +30mV was continuously
recorded before and after rapid application of 10mM Ni2+. During the subsequent 2-meSATP
exposure, the myocyte was held at -80mV to promote Na+ entry. After 3-4 min, the holding
potential was changed to +30mV again and the Ni2+ was applied to block the Ca2+ entry
mode of INCX.

2.2.2.2 Na+-K+ ATPase current (Ip) measurement
Myocytes were voltage-clamped with the same pipette solution as in INCX experiments.
Pipette Na+ was varied from 5-100 mM by equimolar adjustment of Cs+ and Na+
concentrations. After electrical contact was established and the membrane capacitance was
obtained, the bath solution was then changed to a zero-K+ Tyrode’s solution to block Ip. The
solution also contained 5mM NiCl2 to block INCX and ICaL.69, 70 The holding potential was set to
-80mV to promote the 2-meSATP-induced inward current. Ip was measured as the K+activated outward current elicited by rapidly changing the extracellular solution from zero-K+
to 5.4 mM K+-modified Tyrode’s solution for 5 s. The holding potential was switched to 20mV to obtain the maximal activation of Ip. Peak Ip was selected to evaluate Na+-K+ATPase
activity before and after 2-meSATP application, since the Na+ changes sensed by Na+-K+
26

ATPase are more accurately reflected by peak Ip than the steady Ip.69 The brief exposure to
extracellular solution minimized the change of intracellular ion environment during 2meSATP application. After the peak Ip was obtained at control, 3µM 2me-SATP was added
to the superfusion solution for 3-4 min while the myocyte was clamped at -80mV and then
the peak Ip was measured again. Peak Ip after 5 min washout was also obtained.

2.2.3

Cell shortening measurement
Cell shortening (CS) of ventricular myocytes was elicited by field stimulation at 0.5 Hz

and was detected by a video edge-detector device (Crescent Electronics, Sandy, UT) as
previously described.66

2.2.4

Data and Statistics
INCX and Ip (pA) were normalized to membrane capacitance (pF). All data are shown

as mean± SEM. Student’s t test for paired samples was used for statistical analysis, unless
otherwise indicated.

2.2.5

Mathematical Simulation
Simulated current I-V relationships for INCX and Ip are based on previous

formulations.71 The equation for Ip is 𝐼𝑝 = 𝐼�𝑝 × 𝑓𝑝 ×
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, where the last

two terms describe pump dependence on [Na+]i and [K+]o, and the 𝑓𝑝 term defines the
dependence of the pump current on voltage: 𝑓𝑝 =
1
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− 1), and shows that the voltage dependence can be

further modified by extracellular Na+ concentration. In our case, the maximum Ip current, 𝐼�𝑝 ,

is set to 1.88 pA/pF based on the maximum calculated from our own Ip vs. [Na+]i plot (Figure
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1D), instead of the 1.5 pA/pF from the publication. All other parameter values are replicated
from the original publication or given by experimental conditions: 𝐾𝑚,𝑁𝑎𝑖 = 10mM,

𝐾𝑚,𝐾𝑜 =1.5mM, [K+]o =5.4mM, [Na+]o=140mM, [Na+]i is 10mM for the basal condition and set
at 11.2mM to simulate effect of 2-meSATP treatment.
INCX is defined by the equation 𝐼𝑁𝐶𝑋 = 𝑘𝑁𝐶𝑋 ×
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concentration values, half saturation constants, c and the original values for η and 𝑘𝑠𝑎𝑡 (which
are the voltage dependence and negative potential saturation factors for INCX respectively),

an overall scaling factor 𝑘𝑁𝐶𝑋 was estimated to fit our INCX data using a least squares fitting
method in Excel.

2.2.6

Materials
KB-R7943, 2-[2-[4-(4-nitrobenzyloxyl)phenyl]ethyl]isothiourea, and 2me-SATP, 2

methylthio-ATP, were obtained from Sigma Aldrich, Corp (St. Louis, MO, U.S.A). YM-244769,
N-(3-aminobenzyl)-6-{4-[(3-fluorobenzyl)oxyl]phenoxy} nicotinamide, was obtained from
Tocris Bioscience (Bristol, United Kingdom).
c

Glossary of Equation Terms and Values
F
Faraday constant, 96,500 coulombs/mol
𝑓𝑝
voltage-dependence parameter of Ip
𝜎
[Na+]o-dependence parameter of 𝑓𝑝
η
Factor controlling voltage dependence of INCX, 0.35
Saturation factor for INCX at very negative potentials, 0.1
𝑘𝑠𝑎𝑡
𝐼�𝑝
Maximum Na+-K+ ATPase current
𝐾𝑚,𝐾𝑜 K+ half-saturation constant for Ip, 1.5mM
𝐾𝑚,𝑁𝑎𝑖 Na+ half-saturation constant for Ip, 10mM
𝐾𝑚,𝑁𝑎 Na+ half-saturation constant for INCX, 87.5mM
𝐾𝑚,𝐶𝑎 Ca2+ half-saturation constant for INCX, 1.38mM
𝑘𝑁𝐶𝑋 Scaling factor of INCX
R
gas constant, 8.314 J/(°K×mol)
T
absolute temperature, °K
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2. 3 RESULTS
2.3.1

Agonist activation of P2X4R increased peak Ip

Na+-K+ ATPase activity was measured in P2X4R OE ventricular myocytes using the protocol
described in Figure 1A. Thus, 3 µM 2-meSATP induced an inward current (1.4 ±0.36 pA/pF)
in 11 of 17 P2X4R OE myocytes (from 9 P2X4R OE mice) confirming our previous results.47
In these myocytes, the effect of P2X agonist on Ip was determined with 10 mM pipette [Na+]
(Figure 1B). In response to 3 µM 2-meSATP, Ip peak increased to 0.58±0.03 pA/pF from a

Figure 2.1 Peak Na+-K+ ATPase current increases after 2-meSATP application in P2X4
receptor-overexpressing cardiac myocyte. (A) Upper panel shows rapid solution change
protocol with 5.4mM [K+]o to elicit K+-activated Ip; lower panel is membrane voltage. Ip is
recorded at -20mV and 2me-SATP was applied at -80mV. CTR: control; WO: washout. (B)
upper panel: individual traces in a typical myocyte showing the increase of [K+]o -activated Ip
after 2me-SATP application; lower panel: superimposed traces of Ip in control and in 2meSATP. (C) Peak Ip, normalized by cell capacitance, is presented as mean±SEM. The
average control peak Ip differed from that with 2me-SATP. (D) Relationship between peak Ip
and pipette [Na+]. Peak Ip was elicited by switching [K+]o from 0 to 5.4mM at -20mV; pipette
Na+ was varied as shown. Normalized peak Ip is presented as mean±SEM. The number of
cells is indicated in the parentheses (from 18 P2X4R OE mice).
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baseline value of 0.52 ±0.02 pA/pF (P<0.05, Figure 1C), consistent with increased K+activated Na+ pump activity. We next estimated the increase in intracellular Na+ that could
result from the P2X agonist-mediated increase in Ip. To do this, stepwise increments of
pipette [Na+] were made and increases in Ip determined (Figure 1D). The data describing the
relationship between pipette [Na+] and Ip were fitted by the Hill equation where I=Imax *
[Na+]ph/(Kdh + [Na+]p h) and [Na+]p is Na+ concentration in the pipette. The Kd value for [Na+]
from the equation was 17.6mM, similar to the value obtained by others.69 Accordingly, back
calculating from this equation, the 0.06±0.01 pA/pF net increase in peak Ip would correspond
to a 1.08±0.27mM increase of intracellular Na+ during agonist application.

2.3.2

P2X agonist enhances Ca2+ entry mode of INCX
The NCX current is known to be Ni2+-sensitive,61 and was isolated in this manner

after taking measures to block other large currents of the cell. After recording the baseline
Ni2+-sensitive current, 3µM 2me-SATP was applied to myocytes held at -80mV for 3-4 min.
An inward current was observed in 10 of 15 P2X4R OE myocytes (1.3±0.41pA/pF, from 8
P2X4 OE mice, Figure 2A). These 10 myocytes were further tested for an effect of the P2X
agonist on INCX by rapidly adding 10mM NiCl2 to calculate the Ni2+-sensitive current in the
presence of 2me-SATP. Data in Figure 2 B and C show that 2-meSATP caused an increase
in Ni2+-sensitive current at positive potentials (0.55±0.09 pA/pF at control vs 0.82±0.14pA/pF
with 2-meSATP at 50mV, P<0.05). The P2X agonist had minimal effect on INCX at the
negative potentials (-0.46±0.06 pA/pF at control vs -0.45±0.05pA/pF with 2-meSATP at 80mV). These data indicate that 2-meSATP caused an increase of INCX, notably in its Ca2+
entry mode, helping extrude Na+ in exchange for Ca2+.
From the I-V relationships of Ni2+ -sensitive currents, the reversal potential of INCX
shifted from -14±2.3mV under control condition to -25±4.1mV in response to 2-meSATP in
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these myocytes. We next calculated the change of intracellular Na+ that would cause such a
shift of the INCX reversal potential from the following equations.
ENa-Ca = 3*ENa-2*ECa
ENa= (RT/F)*ln[Na+]o/[Na+]i
ECa=(RT/2F)*ln[Ca2+]o/[Ca2+]i
In the calculation, the intracellular resting Ca2+ was artificially kept at 100 nM. With a
negative shift of approximately 11±3.52 mV in the reversal potential of INCX after 2-meSATP,
intracellular Na+ sensed by the NCX would need to increase by 1.28±0.42 mM, provided that
[Na+]i before agonist treatment was 10mM as was provided in the pipette solution. If the
resting Ca2+ were presumed to be 50 nM, the intracellular Na+ sensed by the NCX would still
increase by 1.0±0.34 mM. The subsarcolemmal [Ca2+]i is difficult to estimate even if there is
10 mM EGTA in the pipette solution. This is due to the fact that EGTA is relatively ineffective
in buffering Ca2+ within 20-100 nm of the pore 72. Under the physiological condition of a living
cardiac myocyte, 2-meSATP may cause an increase, even small, of intracellular Ca2+ level
via a direct calcium entry through the P2X4R. Under this circumstance, the estimated
1.28±0.42 mM increase of Na+ in the subsarcolemmal space might be under-estimated.
Overall, while we could not be certain of the exact subsarcolemmal Ca2+ level, whatever the
presumed level of Ca2+, [Na+]i would have to increase to cause the observed shift of NCX
reversal potential. The fact that this estimate from NCX measurements is remarkably similar
to that obtained from Ip measurements provides additional confidence in the value obtained.
To verify that 2-meSATP increases Ca2+ entry mode INCX, the Ni2+-sensitive current
was measured at a holding potential of +30mV without running the ramp protocol before and
after 3 µM 2me-SATP application (Figure 2D). At 30 mV, the Ni2+-sensitive current increased
from 0.28±0.04pA/pF in control condition to 0.48±0.06pA/pF (P<0.05) after 2me-SATP
(Figure 2E). Thus, by either voltage ramp or step, P2X agonist elicited an increase in Ca2+
entry mode INCX.
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Figure 2.2 Calcium entry mode of Na+-Ca2+ exchanger is increased with 2-meSATP.
INCX, represented by Ni2+-sensitive current, in P2X4R OE ventricular myocytes was
determined. (A) Representive trace is shown for membrane current when 10mM Ni2+ was
applied (time period bracketed by down and up arrows) under control conditions, during
2me-SATP application and after washout (WO). (B) Upper panel: descending voltage ramps
from 80mV to -100mV were used to contruct the I-V relationship. Lower panel: typical traces
of membrane currents are shown in control (CTR) and in the presence of Ni2+. (C) Mean I-V
relationships of the Ni2+-sensitive current in control (filled squares) and in the presence of
2me-SATP (open circles). *P<0.05, N=10 from 8 P2X4R OE mice. (D) 2me-SATP increases
Ca2+ entry mode INCX. Representative traces were shown for the Ni2+ -sensitive currents at
+30mV before and after 2me-SATP application in a P2X4R OE myocyte. E: Plot of Ni2+sensitive current at +30mV at control and during 2me-SATP application (P<0.05 N=7 cells
from 5 P2X4R OE mice)
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2.3.3

Simulated I-V relationships
The experimental data indicate that elevation of [Na+]i by P2X4R activation results in

an increase of Ip and of INCX. We asked whether a simulated rise in [Na+]i of the same
magnitude can cause an increase of Ip and INCX like that observed experimentally in P2X4R
overexpressing myocytes. In simulations (see Methods), when the cellular Na+ was
increased by 1.2 mM, a magnitude similar to that estimated by the experimentally measured
stimulation of INCX or Ip by 2-me-SATP, the predicted I-V relationship of Ip matched closely
the experimentally observed increase in Ip (Figure 3A). Similarly, the computationally derived
I-V relationship of INCX agreed well with our experimental results (Figure 3B). Thus, based on
established mathematical models for NCX and Na+ pump,71 the increase in [Na+]i and its
corresponding stimulation of INCX and Ip agreed well with our experimental results.
We modified the scaling factor from 1.5 pA/pF in the original equation for Ip model71
to our experimentally measured maximum Ip current at 1.88 pA/pF. In the computerized
model, Ip is outwardly directed over the entire test potential range (-80 to +50 mV) and is
increased following a 1.2 mM increment of intracellular Na+ (Figure 3A). At -20 mV, the
predicted increase in Ip, 0.04 pA/pF, is similar to the experimentally determined increase of
0.06±0.01 pA/pF following stimulation by 2me-SATP.
In the modeling of INCX, the best fit for our experimental INCX data led us to use a kNCX
of 2606.64 pA/pF instead of 2000 pA/pF used by others.71 The modeled I-V relationship of
NCX shifted leftward upon the 1.2mM step increase of intracellular Na+ from 10 mM to 11.2
mM. This leftward shift was not a parallel change since the primary effect was an increase
in Ca2+ entry mode of INCX with little if any change of the Ca2+ exit mode. The computationally
simulated shift of the I-V curve for INCX was similar to the experimentally observed shift by 2meSATP (Figure 3B). At +50 mV, the modeled Ca2+ entry mode increased from 0.60 pA/pF
at 10mM [Na+]i to 0.86 pA/pF at 11.2mM [Na+]i (0.26 pA/pF net increase). This modeled
increase agrees well with that observed experimentally (0.27±0.10 pA/pF net increase,
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Figure 2C). Overall, an elevated intracellular Na+ level has a more detectable effect on the
Ca2+ entry rather than the Ca2+ exit mode of INCX.

Figure 2.3 Simulated I-V relationships with intracellular [Na+] change. (A) Simulation for
Ip with [Na+]i taken as cellular (pipette) Na+ of 10 mM (solid line) and 11.2 mM (dotted). (B)
Simulation for INCX with [Ca2+]i kept constant at 100nM for cellular Na+ of 10 mM (solid line)
and 11.2 mM (dotted). The actual experimental data under control (solid squares) and after
2me-SATP application (open circles) were also plotted for comparison to the simulation.

2.3.4

KB-R7943 or YM 244769 inhibits 2me-SATP-induced increase of cell shortening
Extracellular 2-meSATP increases CS in P2X4R OE cardiac myocytes.51 To explore

if the Ca2+ entry mode of NCX contributes to the increase of CS by 2-meSATP in P2X4R OE
cardiac myocytes, KB-R7943 and a structurally different NCX inhibitor YM 244769,73 which
preferentially oppose the Ca2+ entry mode, were tested in P2X4R OE myocytes. KB-R7943
at 5 µM or YM-244769 at 0.1 µM did not alter the basal cell shortenings of the P2X4R OE
myocytes (total of 19 myocytes from 7 P2X4R OE mice, Figure 4B), similar to previous
observation.74 It was shown that while NCX-mediated Ca2+ influx could be blunted with 5µM
KB-R794, baseline contraction remained unaffected.74 Superfusion with 3 µM 2me-SATP
increased CS by 29.2±3.7% above basal in 16 of 23 P2X4R OE cardiac myocytes paced at
0.5 Hz (P<0.05, from 10 P2X4R OE mice). When 5 µM KB-R7943 was added in the
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continued presence of 2me-SATP, the increase of CS was reduced to 13.8±3.9% above
basal (P<0.05, Figure 4A and 4C). In another set of similar experiments, we tested the effect
on 2-me-SATP-stimulated CS by YM-244769. In these studies, 3 µM 2me-SATP increased
CS by 31.4±7.1% in 10 of 15 P2X4R OE cardiac myocytes paced at 0.5 Hz (P<0.05, from 6
P2X4R OE mice). At 0.1 µM, YM-244769 reduced the 3 µM 2me-SATP-stimulated CS to
17.3±7.4% above basal (P<0.05, Figure 4D). Thus, either KB-R7943 or YM-244769 could
inhibit the 2me-SATP-induced increase of CS, indicating a role of NCX Ca2+ entry mode in

Figure 2.4 Preferential calcium entry mode blockers of the Na+-Ca2+ exchanger inhibits
2me-SATP-induced increase of cell shortening. (A) Representative traces of cell
shortening (CS) in P2X4R OE myocytes paced at 0.5 Hz are shown for cells exposed to
2me-SATP and then to 2me-SATP plus KB-R7943 (KBR), followed by washout. (B) Basal
CS did not change after application of KB-R7943 (N=12) or YM-244769 (N=7). (C) Percent
increases of CS above basal during application of 2me-SATP alone (N=16 cells, 10 P2X4R
OE mice) was blunted during addition of KB-R7943 plus 2me-SATP. (D) Percent increases
of CS above basal during application of 2me-SATP alone (N=10 cells, 6 P2X4R OE mice)
was higher than that during exposure of YM-244769 (YM) plus 2me-SATP. P<0.05 for all bar
indicated pair comparisons in panels C & D.
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mediating the P2X agonist effect on myocyte contractility in these P2X4R OE myocytes.

2.3.5

P2X agonist can stimulate INCX in WT ventricular myocytes
To explore the physiologic relevance of this receptor in modulating Na+ handling,

the effect of P2X agonist on INCX and myocyte contraction were tested in cardiac ventricular
myocytes from WT mice. Application of 10 µM 2me-SATP induced an inward current at 80mV (0.68±0.26pA/pF) in 8 of 34 WT ventricular myocytes (from 7 WT mice), similar to our
previous findings.47 These P2X agonist-responsive myocytes were then tested for changes
in INCX. 2me-SATP increased Ni2+-sensitive current at positive potentials (0.46±0.05 pA/pF at
baseline vs 0.59±0.06pA/pF with 2me-SATP at +50mV, P<0.05, Figure 5A). There was no
significant change induced by 2me-SATP in Ni2+-sensitive current at negative potentials (0.40±0.09 pA/pF at control vs -0.42±0.09pA/pF with agonist at -80mV, P>0.05). The primary
effect on the Ca2+ entry but not the exit mode of NCX in WT myocytes is essentially the
same as that found in myocytes from P2X4R OE hearts. The reversal potential of INCX shifted
from -13.25 ±1.72 mV to -17.5±1.29 mV in response to 2me-SATP (P<0.05). These data
demonstrate that P2X agonist can also elicit an increase in NCX Ca2+ entry mode in some
WT myocytes.
As further evidence for a physiological role of cardiac P2X4 receptors, the effect of
KB-R7943 on the P2X agonist-induced increase of CS was tested in WT murine cardiac
myocytes. In WT myocytes, P2X agonist has little or no effect on basal contraction. To
facilitate detection of an agonist-stimulated effect on CS in WT myocytes, 3 µM ivermectin,
which selectively potentiates the P2X4 effect,63 was combined with 10 µM 2me-SATP. The
combined presence of 2me-SATP and ivermectin increased CS by 14.8±3.1% above basal
in 8 of 32 WT paced at 0.5 Hz (P<0.05, from 7 WT mice). Adding 5 µM KB-R7943 to 2meSATP plus ivermectin reduced the CS to 7.2±2.3% above basal (Figure 5B, P<0.05), similar
to the response elicited by KB-R7943 in the P2X4R OE myocytes. The data support a role of
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Ca2+ entry NCX mode in mediating the P2X4 receptor-induced increase of CS in WT
myocytes.

Figure 2.5 The link between P2X receptors and NCX in WT myocytes. (A) 2me-SATPinduced increase of INCX in WT myocytes. Ni2+-sensitive currents before and after 2me-SATP
application are presented at membrane potentials of -100, -80 , 50 and 70mV. INCX at +50
mV and +70mV were significantly larger in the presence of 2me-SATP than in control
(*P<0.05, N=8 cells, 7 WT mice). (B) Percent increases of CS above basal were shown
during application of 2me-SATP plus ivermectin (Ive) (N=8 cells, 7 WT mice) and during the
subsequent exposure of KB-R7943 (KBR) plus 2me-SATP and Ive (% above basal with KBR
plus 2me-SATP and Ive vs that by 2me-SATP plus Ive, P<0.05).

2.4 DISCUSSION
Belonging to a family of ligand-gated ion channels, P2X4 receptors are an important
subtype of the endogenous P2X receptor channel in the cardiac myocyte. When activated
by extracellular ATP, these channels conduct cations in a voltage-dependent manner with a
reversal potential near 0 mV.63, 64 As a Na+ entry pathway, these channels may have a
physiological role in regulating cellular Na+ levels in cardiac myocytes. The objective here
was to test the hypothesis that activation of these channels by extracellular ATP causes an
increased cellular Na+ level in cardiac myocytes. We further determined whether the P2X
receptor-induced stimulation of NCX has a role in modulating the contractile state of cardiac
myocytes.
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In the present study, we used myocytes from both P2X4R OE and WT mice to test
these concepts, which are supported by the following lines of evidence. First, the P2X
receptor-mediated increase in Na+ entry into the myocyte47 should stimulate Ip because the
pump functions to extrude intracellular Na+. Indeed, activation of the P2X4R by its agonist 2meSATP was able to increase Ip in P2X4R OE cardiac myocytes. Second, P2X agonist
should stimulate INCX, another cellular mechanism for Na+ extrusion. We found that in both
WT and P2X4R OE cardiac myocytes, 2-meSATP could stimulate the Ca2+ entry mode of
NCX. Third, an increase in [Na+]i due to P2X receptor-mediated Na+ entry can be estimated
in P2X4R OE myocytes. For Ip, which was only measured in P2X4R OE myocytes, the
magnitude of [Na+]i increase, 1.08±0.27 mM, was calculated based on responses calibrated
to concentration changes in pipette and hence in cytosolic Na+. For INCX, the receptormediated shift of reversal potential yielded a 1.28±0.42 mM Na+ increase, assuming a
constant intracellular [Ca2+]. These data provided experimental evidence under voltage
clamp condition that stimulation of P2X receptors can result in measurable cellular Na+
increases. Fourth, computational modeling, assuming an increment of [Na+]i like that
observed experimentally, replicated the experimental findings and permitted estimation of
the pattern and magnitude of increases in Ip and INCX. The simulated effects on Ip and INCX
from the increase in [Na+]i were similar to previously established dependencies of these
currents on ionic concentrations and voltage. Experimentally, the activation of the P2X4
channel primarily increased the Ca2+ entry mode of NCX. Computationally simulated INCX I-V
relationship in response to a similarly increased cellular [Na+] also showed an increase in
only the Ca2+ entry mode. There was minimal effect on Ca2+ exit mode of NCX in the
simulation. Overall, the computer simulation agreed with experimental data regarding the
cellular ionic effects on Ip and INCX. P2X agonist also induced a similar pattern of increase in
Ca2+ entry mode of NCX in cardiac ventricular myocytes of WT animals, supporting a
physiological role of the cardiac P2X receptor in regulating Na+ handling.
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We attempted to measure directly the [Na+]i in P2X4R OE myocytes using the
fluorescent Na+ indicator SBFI. We could not detect any change in the intracellular Na+
concentration after 2me-SATP application in P2X4R myocytes (data not shown). This is not
surprising given that the amount of cellular Na+ increase is below the sensitivity of this Na+sensitive dye, the Kd of which is 3.8mM in the absence of K+ and 11.3 mM in the presence of
physiological concentrations of K+ (Molecular Probe website). Swift et al observed that a low
concentration of ouabain (0.3 µM) increased contractility by 40% via its selective inhibition of
the α2-isoform of Na+ pump but they could not detect an increase in global [Na+]i by SBFI in
rat cardiac myocytes.75 They concluded that the increased contractility in response to 0.3 µM
ouabain could not be explained by a substantial global rise in [Na+]i. Similar to our finding of
a P2X agonist-induced stimulation of NCX, a local accumulation of [Na+]i after ouabain was
detectable by INCX measurements.75 It is thought that the Na+ concentration in the
subsarcolemmal space is sensed by the Na+ pump, NCX, and other membrane transport
mechanisms.76-78 It is possible that the increase in INCX or Ip measured during cardiac P2X4R
activation reflects an increase in the subsarcolemmal Na+ concentrations.
In studying the role of NCX in mediating the P2X receptor-induced effect on
contraction, we used P2X4R-overexpressing cardiac myocytes. The P2X4R OE myocytes
displayed a greater magnitude of P2X receptor-mediated increase in contraction and were a
better model to determine the mechanism of contractile effect of P2X agonist. We postulated
that Ca2+ entry mode of NCX, stimulated by intracellular Na+ elevation, contributes to
contraction increase by P2X agonist. This postulate is supported by our finding that P2X
agonist was able to enhance sarcoplasmic reticulum Ca2+ content in P2X4R OE myocytes.55
In the present study, KB-R7943 could inhibit the 2me-SATP-induced increase in CS in
P2X4R OE myocytes. KB-R7943, at 5 µM, can serve as a selective Ca2+ entry mode
inhibitor.74, 79 Another structurally different selective inhibitor of the Ca2+ entry mode, YM-

39

244769,73 was also able to inhibit the 2me-SATP stimulation of CS in the P2X4R OE cells.
Neither KB-R7943 nor YM-244769 affected the basal CS in these cardiac myocytes.
Several considerations deserve to be mentioned. Ca2+ may enter directly through the
P2X4R, and could contribute as much as 8% of the total inward current induced by ATP via
the human homotrimeric P2X4R.65 Direct Ca2+ entry via the P2X receptor may impact
dynamically the cellular Na+ by further increasing the accumulation of Na+ that enters
through the receptor under physiological condition in myocytes. We could not exclude that
P2X agonist increases subsarcolemmal [Ca2+]i via direct calcium entry through the receptor
channel. A direct measurement of subsarcolemmal [Ca2+]i during P2X agonist stimulation
was not feasible in the present study.
Another implication of P2X receptor activation merits further consideration. That
both INCX and Ip can extrude the P2X receptor-mediated Na+ entry distinguishes the P2X
effect from the contractile and pro-arrhythmic effects of digitalis. Digitalis, by inhibiting the
Na+-K+ ATPase and thus causing an increase in intracellular Na+, results in NCX as the only
Na+ extruding mechanism in digitalis-treated cardiac myocytes. Since both INCX and Ip can
operate to extrude P2X receptor-conducted Na+ entry, the cell is less likely to be overloaded
by intracellular Na+ and Ca2+ during stimulation of P2X receptors. Finally, the physiological
relevance of cardiac myocyte P2X receptor is supported by the demonstration in WT cardiac
myocytes that P2X agonist can stimulate NCX and that inhibition of Ca2+ entry mode of NCX
could reduce P2X4 receptor-induced contraction in these cells.

40

Chapter 3
P2X Agonism leads to Limited Cardiac Myocyte
Excitability

3.1

INTRODUCTION
As discussed earlier and demonstrated in the previous chapter, P2X receptors allow

passage of cations, the majority of which are Na+, into cells. They are thus capable of causing
depolarization and calcium increase in many cell types to initiate signaling. The consequence of
this seemingly simple event becomes more difficult to envision when imposed on a cardiac
myocyte, whose function uniquely relies on tightly regulated cycles of action potential (AP) firing
and calcium transients. How these highly dynamic cycles are affected by the relatively slower
changing P2X current is not well characterized.
We have shown that P2X driven electrophysiological changes can underlie an
enhancement of contraction in cardiac myocytes, and this may be important in maintaining
cardiac pump function during ischemic injury and in the critical period after injury.
Overexpression of P2X4R protects against calsequestrin overexpression-induced and postinfarct heart failure.1, 52 On the other hand, inward cation passage can increase cellular
excitability and lead to spontaneous activity that is undesirable for the controlled rhythm of the
heart. There exists a conceptual gap regarding how inotropic enhancement may occur without
significant electric disturbance. Here we consider the dynamics of P2X activation and study its
impact on cardiac function in an integrated framework of excitation contraction coupling.

41

3.2

MATERIALS AND METHODS

3.2.1 Computational Simulation of the P2X current in the context of a Single Cardiac
Myocyte
An ordinary differential equation-based model of the mouse cardiac myocyte, previously
developed by Bondarenko, et al15 was implemented in the Virtual Cell simulation software80 and
modified to include an additional flux representing the P2X channel. The simulated P2X current
follows the general shape of the previously determined I-V relationship47 (Figure 3.1A) and is
desensitized with an exponential function with modifiable time constant. Simulations were run
for 1000s with 1Hz pacing for values to reach relative steady state, and the end results were
copied into new simulations as initial values. VCell outputs for select model parameters were
exported and plotted.

3.2.2

Animals
P2X4 receptor overexpression (P2X4R OE) mice were generated and bred as previously

described.51, 55, 66 All animal handling protocols have been approved by the Institutional Animal
Care and Use Committee at the University of Connecticut Health Center.

3.2.2.1

P2X4R Knockout Animals

The Cre-Lox recombination technology was employed for P2X4R gene targeting.81 The
first loxP site was inserted into intron 4 and the second loxP site together with the Frt-PGKneoFrt cassette was inserted in intron 1, in a direction opposite to the transcription of P2X4R. The
targeting vector was electroporated into embryonic stem cells, which were derived from F1
(129Sv/C57BL6J) blastocysts. Chimeric animals were generated by aggregating targeted ES
cells with CD1 morula. The PGKneo cassette was removed by breeding chimeric males with
ROSA26-Flpe females (Jax stock no: 009086) to generate P2X4floxed/+ F1 pups. F1 mice were
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backcrossed with C57BL6 mice for over ten generations to produce P2X4floxed/floxed mice in the
C57BL6 background.
Homozygous P2X4floxed/floxed males were then bred with heterozygous females with
widespread expression of the Cre recombinase, including in the unfertilized egg (129S1/SvHprttm1(cre)Mnn/J; Jax stock no. 004302 bred to the C57BL6 background) to produce P2X4floxed/+ F1
pups with Cre-excised floxed gene, which were crossed together to generate homozygous
global P2X4R knockouts. Genotyping was carried out using primers listed in Appendix A Table 1,
and immunoblotting confirmed protein decrease.

3.2.3

Measuring Voltage with Single Cell Patch Clamp
Myocytes from 8-16 week old WT and P2X4R OE mice were obtained and placed in a

small superfusion chamber on the stage of an inverted microscope. For isolation procedure,
refer to Section 2.2.1. Rod-shaped myocytes with clear striations and without spontaneous
contraction are considered healthy cells for experimentation. Whole-cell patch clamp was
established with a K+-based pipette solution (in mM: 120 potassium aspartate, 30 KCl, 5
Na2ATP, 1 MgCl2, 10 HEPES, and 10 EGTA, pH 7.3 adjusted with KOH) to maintain
physiological internal conditions for subsequent voltage examination. 2-meSATP or control
buffer solution was given via rapid perfusion (SF-77B, Warner Instrument) to quiescent or
stimulated (action potentials elicited with current injection) cardiac myocytes in current-clamp
mode. Generation of protocols and acquisition of data were carried out in pCLAMP10 (Axon
Instruments). For characterizing initial depolarization in response to P2 agonism, each cell was
only exposed to 2-meSATP once to avoid desensitization effects. In a subset of experiments, 2meSATP was withdrawn after some time to establish washout of drug, where as in other
experiments 2-meSATP was delivered continuously for 10 minutes to examine natural
desensitization.
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3.2.4

Ex Vivo Working Heart for monitoring Whole Heart Function
Mice 8-16 weeks in age from both sexes were anesthetized with a ketamine/xylazine

mixture before the chest was opened and the heart, with all major vessels and lungs attached,
excised for immediate cannulation of the aorta. The viability of the heart was maintained with
oxygenated Krebs-Henseleit bicarbonate buffer (in mM: 119 NaCl, 25 NaHCO3, 4 KCl, 1.2
KH2PO4, 1 MgCl2, 1.8 CaCl2, 10 glucose and 2 Na-pyruvate; pH adjusted to 7.4 by bubbling with
95% O2 and 5% CO2) in the Langendorff mode while the pulmonary vein was cannulated and a
pressure transducer was inserted into the left ventricle. After the heart was stably mounted,
retrograde perfusion through the aorta was switched to antegrade perfusion via the pulmonary
vein, establishing the working heart mode. The afterload against which the perfusate is ejected
from the left ventricle was set to be constant with a column of buffer connected to the aorta.
Hemodynamic parameters were derived from digitized pressure traces and analyzed in
LabChart Pro (ADInstrument). In a number of experiments, electrodes were placed at the right
atrium and left ventricle for a 2-lead electrical rhythm recording. After a stabilizing period with
drug-free perfusate, 2-meSATP of a given concentration between 10nM to 100uM was
administered for 10 minutes. Hearts were allowed to beat at their intrinsic pace. Those with
baseline heart rate under 250 beats per minute were excluded from further experimentation.
Additional experiments were performed on P2X4R KO hearts at 1µM of 2meSATP to further test
differences seen between WT and P2X4R OE animals.

3.2.5

Quantification of Ectopic Activity
Abnormal beats were detected using the heart rate variability module of LabChart Pro.

Deviations from normal heart rate are easily visualized using the tachogram, which plots
successive R-R intervals over time. Ectopic beat detection was confirmed with visual inspection
of the tachogram and the raw recording trace. The numbers of ectopic beats 10 minutes before
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and after drug application were recorded. Hearts with greater than 5% of its baseline beats
classified as abnormal were excluded from further analysis.

3.2.6

Data Analysis and Statistics
Patch-clamp data were analyzed using Clampfit 10.0 (Molecular Devices, CA, USA) and

exported to GraphPad Prism for graphs. Pressure traces from isolated working hearts were
analyzed in LabChart Pro. Pressure parameters from beat cycles were averaged every 5
seconds, and data were normalized to 4 minutes before drug application for percent change
from baseline. Data are reported as mean ± standard error of the mean (SEM). Paired t-test
was used to compare drug effects, and differences between genotypes were compared with two
tailed, unpaired t-tests. The level of significance is taken as being P<0.05.

3. 3 RESULTS

3.3.1

Computational modeling predicts enhanced cardiac myocyte excitability with P2X

activation
Simulations demonstrated that P2X activation can evoke a spectrum of outcomes for
calcium transients that result in its eventual enhancement, consistent with the suggestion that
P2X activation can enhance contraction in cardiac myocytes. However, the initial cellular
response can be variable, depending on P2X current characteristics and other cellular factors.
Select simulation outputs are displayed in Figure 3.1. The P2X current was assumed to be 90%
carried by Na+ and 10% by Ca2+ ions, and the desensitization constant was assumed to be 60
seconds in these simulations. Mimicking turning on the P2X current at 150 seconds into the
simulation in WT cardiac myocytes (Figure 3.1A open circles showing previous experimental
data for WT, and solid data illustrating simulated I-V relationship for a representative WT
myocytes), AP generation was not significantly altered except for a slight initial depolarization,
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Figure 3.1 Computational predictions of P2X induced action potential and calcium changes. (A) Simulated I-V curves as
compared to previously experimental data from WT (open circles, simulated results in solid line) and P2X4R OE (closed circles,
simulated results in dashed line) cardiac myocytes. (B) Simulated cardiac myocyte response to activation of P2X current in WT
cardiac myocyte showing slight resting membrane depolarization that does not disrupt action potential generation and gradual
enhancement in calcium transients. (C) Simulated voltage and calcium response to activation of current in P2X4R OE cardiac
myocyte. Membrane depolarization is large enough to initially blunt normal AP generation and calcium cycling, but normalizes over
time.

while corresponding calcium transient trace demonstrate increase over baseline (Figure
3.2B). At a conductance level similar to what we measured previously in the P2X4R OE
cardiac myocytes (Figure 3.1A closed circles and dashed line), opening of the P2X channel
can lead to an initially large depolarization from rest, temporarily attenuating stimulated APs
and beat-to-beat calcium cycling (Figure 3.1C). A number of ectopic action potentials are
seen in the simulation data, due to partial opening of fast Na+ channels. But given that the
P2X receptor desensitizes, these disruptions are transient and enhanced calcium transients
were observed when APs normalized. These results are in contrast to our earlier conclusion
that activation of the P2X4 current does not alter cellular excitability, which was based on
observations that P2X4R OE myocytes exposed to 3 minutes of 3µM of 2-mesATP bath
perfusion had no significant change in action potential characteristics at that time point.55
Simulation results thus prompted us to re-examine our previous protocol and to retest
cardiac myocyte excitability and the propensity of arrhythmogenesis in the intact heart in
response to P2X activation.

3.3.2

P2X4R OE myocytes display transient depolarization in response to activation
We performed current clamp experiments with K+-based pipette solutions in order to

investigate whether inward current activated by 2-meSATP were able to induce changes in
resting membrane potentials and modulate the excitability of ventricular myocytes. Rather
than using gravity based bath application of 2-meSATP, we employed a fast switch system
that allowed us to pinpoint the drug application to a sub-second scale. In resting P2X4R OE
myocytes, we observed prompt depolarization responses to pulses of 2-meSATP (Figure
3.2A). Note that none of the subsequent depolarizations were larger than the initial
depolarization, suggesting that desensitization is observed with each pulse of agonist
application, which is further supported by the observation that a longer off time between two
pulses led to greater recovery. More prolonged 2-meSATP application caused immediate
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membrane depolarization that slowly normalized over minutes (Figure 3.2B).

Figure 3.2 2-meSATP elicits membrane depolarization in P2X4R OE cardiac myocytes.
(A) Example quiescent myocyte in current clamp mode, measuring resting membrane
potential and depolarization caused by 5µM 2-meSATP pulses. (B) More sustained 2meSATP delivery demonstrating normalizing membrane potential in another quiescent
myocyte over 3 minutes. (C) and (D) Examples of myocytes, stimulated every 2s to fire an
action potential. 5µM 2meSATP is administered during action potentials 11 to 20. The
myocyte in (C) experienced less resting membrane depolarization and action potential
alteration than the myocyte in (D). Spikes observed during 2-meSATP application in (D)
likely reflect stimulus current. Overlapped sweep views to the right show difference in action
potential duration between the two cells, pointing to a likely difference in repolarizing
capacities. Black line is pre-drug baseline, red corresponds to maximum depolarization, and
grey line shows recovery.
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To better understand the effect of P2X4 channel mediated depolarization on beating
cardiac myocytes, a 0.5ms current of sufficient magnitude to elicit an action potential (0.52nA) was injected every 2 seconds. Myocytes were recorded for 30 cycles of AP, with 5µM
2-meSATP applied during AP numbers 11-20. The responses of two myocytes are shown in
Figure 3.2 C and D, illustrating the variability in the magnitude of resting membrane
depolarization and effects on action potential generation. While some cells experienced
small depolarizations, others experienced large (>40mV) depolarizations, which then
rendered the cell unable to fire APs in response to subsequent current injections. These
results demonstrate that the purinergic agonist 2-meSATP can trigger immediate
depolarizations in both quiescent and stimulated cardiac myocytes isolated from cardiac
specific P2X4R OE hearts. The general features mimic what would be expected from the
activation of a P2X4 current, namely, fast activation followed by slow desensitization.
There was a clear difference between the response of P2X4R OE cardiac myocytes
and that of the WT cardiac myocytes to stimulation with 2-meSATP (Figure 3.3). A
concentration dependent shift in the proportion of cardiac myocytes that experienced large
depolarizations in response to the agonist was evident in P2X4R OE myocytes. Out of the
ten cells exposed to 5µM 2-meSATP, three experienced >40mV depolarizations. The
average depolarization of these three cells was 49.91±2.05 mV, while the seven cells that
had smaller responses was 4.20 ±0.98 mV, combining for a total average of 17.92±8.63 mV
for 5µM 2-meSATP induced depolarization in P2X4R OE myocytes. A closer examination of
the data suggests that baseline action potential duration may impact myocyte responses to
purinergic agonism, offering insight into the variable cellular response at this lower
concentration of agonist. Myocytes that took longer for action potentials to reach 90%
repolarization (APD90) before drug was added showed greater depolarization in response to
P2X activation, which may reflect relatively blunted repolarization mechanisms in these cells
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(Figure 3.3B). When 100µM 2-meSATP was applied, all tested P2X4R OE cardiac myocytes
displayed large depolarizations, which averaged 51.67±3.34 mV. The mean magnitude of
depolarization and the proportion of cells experiencing large depolarization increased with
increasing concentration of 2-meSATP in the P2X4R OE animals, while the majority WT
myocytes did not experience an immediate depolarization even at 100µM of 2meSATP
(0.74±0.53 mV, n=11, p>0.05 against buffer control; individual data points displayed in

P2X4 OE

P2X4 OE

WT

Figure 3.3 Summary of maximum depolarization in response to 2-meSATP
2-meSATP elicited depolarization in P2X4R OE cardiac myocytes. Maximum resting
membrane depolarization in response to 2-meSATP are plotted against baseline AP
characteristics that may reflect K+ channel activity: (A) Resting membrane potential, and (B)
the time for action potential to recover 90% (APD90). 3 out of 10 cells experienced large
depolarizations in response to 5µM 2-meSATP and APD90 may be a good predictor of this
response. All cells exposed to 100µM 2-meSATP experience large depolarizations. (C) WT
cardiac myocytes did not significantly depolarize in response to 100µM 2-meSATP. (D)
Summary of WT and P2X4R OE immediate cellular depolarization in response to P2
agonism.
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Figure 3.3C, with insert showing magnified voltage scale). However, 8/11 of the WT cells
exposed to 100µM of 2meSATP experienced spontaneous activity at a later point during the
treatment. Buffer control did not elicit significant depolarization in either P2X4R OE
(0.05±0.15 mV, n=5) or WT (0.01±0.20 mV, n=8) cardiac myocytes. These results support a
P2X4 channel mediated depolarization response to 2-meSATP, with concentration
dependent change in the population response.
After establishing that the depolarization response is specific to agonist stimulation of
the P2X4 receptor, we next asked what would happen in the continued presence of agonist.
As predicted by the computational model, desensitization of the P2X current would lead to
normalization of action potential in the continued presence of 2-meSATP, and this was
corroborated by patch clamp data. In 3 of the 4 P2X4R OE myocytes exposed to 100µM of 2meSATP, current injection stimulated action potential firing resumed after 18, 21 and 34
seconds (example cell shown in Figure 3.4B; refer to simulation result in Figure 3.1C
expanded AP graph for comparison). In the other cell where membrane potential did not
recover, the seal was confirmed to be lost after 3 minute. It should be noted that these

Figure 3.4 P2X4R mediated membrane depolarization is transient
(A) Buffer control had no effect on cardiac myocyte APs. (B) P2X4R activation led to
membrane depolarization that initially blunted current injection stimulated AP firing but
recovered over time, with resumption of stimulated APs. Bars indicate presence of treatment
solutions, which were continually applied for 10 minutes. While the recovered APs shown in
(B) are of smaller amplitude compared to baseline, this is not representative of the APs later
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in time as the P2X current continued to desensitize. A full recovery comparable to baseline
would be seen later.
experiments were performed with 10mM EGTA in the pipette solution to buffer intracellular
Ca2+. These findings reveal that while 2-meSATP-evoked inward cationic current via the
P2X4 channel can lead to cellular excitability, direct depolarization effects are temporary.

3.3.3

P2X activation does not increase arrhythmogenesis in Intact Hearts
Because cellular electrophysiological data confirmed that P2X4 channel activation

can rapidly modify myocyte membrane excitability and since others have suggested that P2
agonism can induce serious ventricular arrhythmias, we sought to more carefully examine
this arrhythmogenic potential in intact hearts. Isolated hearts were mounted in the working
heart configuration and allowed to beat at their intrinsic pace. Baseline heart rates were
similar, at 393.4±6.64 (n=64) and 390.7±6.95 (n=53) beats per minute for WT and P2X4R
OE hearts, respectively. We did not observe significant arrhythmic activity in P2X4R OE
hearts as compared to WT at baseline. Eight WT and one P2X4R OE hearts had greater
than 5% of their baseline beats classified as abnormal, and were excluded from analysis of
agonist treatment effect. Most ectopic activities took the form of premature ventricular beats
(Figure 3.5A). Paired t-test comparisons of the effect of 2-meSATP application indicated that
there was a significant increase in the number of ectopic beats in WT hearts at 10µM and
100µM of 2-meSATP (Figure 3.5B). There was a trend towards increased ectopic activity at
the highest concentrations of 2-meSATP in P2X4R OE hearts as well, mainly driven by 3
hearts that had a noticeable increase (>5%) in the number of abnormal beats, but this
increase remains statistically insignificant. These data suggest that 2-meSATP at high
concentrations can increase ectopic action potentials in WT hearts, but P2X4 channel
overexpression in cardiac myocytes does not increase baseline and agonist-induced
arrhythmic activity.
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Figure 3.5 Summary of Ectopic Activity in Intact Hearts
(A) Example electrical and pressure trace from a P2X4R OE heart treated with 100µM 2meSATP. Arrows mark ectopic events. (B) Summary of the increase in the number of
ectopic beats after 2-meSATP application for each individual heart. * denotes significant
increase by paired t-test in WT with 10µM and 100µM of 2-meSATP.

3.3.4

A novel biphasic contractile response to 2-meSATP in murine hearts
In addition to close examination of possible arrhythmic sequelae induced by altered

cardiac myocyte excitability in whole hearts, the working heart setup allowed us to quantify
additional parameters associated with pressure development in the left ventricle. Continuous
2-meSATP treatment led to a surprising, previously undescribed, biphasic response in both
WT and P2X4R OE hearts (Figure 3.6). Control perfusion did not elicit significant change,
and 2-meSATP below 1µM had minimal effect. In response to doses of 2-mesATP 1µM and
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Figure 3.6 2-meSATP leads to dose-dependent biphasic response in the murine heart.
(A) Raw data trace from an example WT heart, treated with 100µM 2-meSATP.
Corresponding 5 second averages recorded for WT hearts exposed to 100µM 2-meSATP
showing percent changes from baseline (bl) in terms of (B) left ventricular pressure height
and (C) heart rate. (D) The pressure and heart rate product (PH*HR) and (E) the maximum
rate of pressure development (+dP/dt, black solid line) and maximum rate of relaxation (dP/dt, gray dashed line) are shown as surrogates for overall cardiac output. (F-J) Summary
of biphasic response showing maximum depression and enhancement changes from
baseline after various doses of 2-meSATP in both WT and P2X4R OE hearts (black circles
for WT, red circles for P2X4R OE; n=15 for each group exposed to 1µM to 100µM; WT
hearts treated with 10nM and 100nM had n=10 per group; P2X4R OE hearts at 10nM and
100nM had n=2 and 7 respectively). (K) Summary of +dP/dt maximum changes from
baseline at 1µM across hearts of all three genotypes (n=11 for P2X4R KO). *P<0.05
indicates significant difference between WT and P2X4R OE for F-J and for the indicated
pairs in K.
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greater, an initial drop in pressure was evident, usually occurring within one minute. The
pressure then recovered and rose higher than the baseline pressure in most cases. Wash
out of drug returned measures to baseline levels or slightly below baseline due to a natural
decline of function over time. Both the depressive and enhancement phases were dose
dependent, and a slowing of heart rate was significant at 100µM of 2-meSATP in both WT
and P2X4R OE hearts (Figure 3.6 C and G). There was no sign of loss of sinus rhythm.
A significant difference between WT and P2X4R OE hearts was consistently
observed at 1µM 2-meSATP, where both the depressive and enhancement phases were
greater in the WT (Figure 3.6F, H, I, J). Further experimentation on P2X4R KO hearts at this
concentration of agonist showed that the biphasic response is persistent in P2X4R knockout
hearts (Figure 3.6K) and was not different from WT response. 1µM 2-meSATP treatment of
P2X4R knockout hearts led to an initial depression in LV pressure followed by recovery and
enhancement in a similar time course and to comparable magnitudes as WT hearts.
Baseline parameters were also not significantly different from WT littermates. The baseline
PH for P2X4R KO hearts was 90.87±3.66 mmHg (vs. 92.85±2.46 mmHg in WT, n=6) and the
HR was 379.5±14.35 beats per minute (vs. 374.6±23.55 in WT, n=6).

3.4

DISCUSSION
Extracellular ATP-activated purinergic receptors have been implicated in different

physiological and pathophysiological events such as platelet aggregation, hypoxia, pain, and
vascular diseases. With increasing interest in targeting these receptors for treating various
aspects of cardiovascular disease, it is important to clarify their effects on cardiac excitability.
While many studies have described the cardiac effects of ATP, reviewed in 82, results are
mixed and remain controversial due to differences in methodology and fast breakdown of the
extracellular nucleotide. It is difficult to ascertain both the composition and concentration of
ATP and its metabolites that reach the heart after bolus injections and in vivo data can be
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complicated by nerve terminal release of ATP as co-transmitters83, 84 and reflexive responses
to sympathetic afferents.85 In this study, in addition to examining P2 agonism in WT animals,
we took advantage of our P2X4R OE transgenic animals to further clarify the effects of
activating these receptors.
At the cellular level, we along with other groups have previously demonstrated
enhanced contraction after 2-meSATP application in a number of studies.42, 49 Others have
observed spontaneous contractions in quiescent myocytes and ectopic beats in electrically
stimulated myocytes in response to P2 agonist that suggest altered cellular excitability.46, 86
Earlier data from our laboratory also established a current-voltage (I-V) relationship caused
by 3µM of 2-mesATP after 3 minutes of bath perfusion and suggested no significant change
in action potential at that time point.55 When we incorporated the previously obtained I-V
relationship into an established murine cardiomyocyte computational model, we observed
immediate depolarization that, in the case of the current magnitude representing P2X4R OE
myocytes, was large enough to blunt subsequent action potential firing. Therefore we
revisited the question of cellular excitability in the P2X4R OE cardiomyocytes with a modified
protocol. Instead of bath application of agonist, as is done in most studies, we employed a
rapid perfusion technique that allowed us to precisely determine the timing of drug
stimulation. With this improved technique we saw immediate depolarization in P2X4R OE
cardiomyocytes that desensitized with prolonged agonist presence both in quiescent and
stimulated myocytes (Figure 3.2B and 3.4B). The EC50 and current
desensitization/resensitization rates of P2X currents in more pure expression systems have
been reported.63 Comparing the range of these values to our data suggests that our
observation is P2X4R-specific. P2X1 and P2X3 are desensitized at a much faster rate, while
P2X5 and P2X6 are thought to have low membrane expression and thus contribute little to
overall agonist-induced current. P2X7 is uniquely stimulated at higher concentrations of
agonist and does not desensitize significantly on the minute time scale. P2X2 has similar
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characteristics as P2X4, and heterotrimeric combinations of P2X subtypes (P2X1/2, 1/4, 1/5,
2/3, 2/6, 4/6, 4/7) are plausible contributors as well, as many have a similarly slow rate of
desensitization or remain uncharacterized.87 However, the lack of response in WT
cardiomyocytes further suggest that the immediate excitation seen in P2X4R OE myocytes
were specific to the activation of the P2X4R channel. Considering the desensitization
characteristics observed in these experiments, it is not surprising that we previously did not
see changes in action potential characteristics after 3 minutes of treatment. Additionally, the
previous experiments were performed with 3µM 2-meSATP, which would stimulate a smaller
population of cells to have large depolarization responses that would significantly affect
electrically stimulated APs. It is of interest to note that 8 out of 11 WT cells that were
exposed to 100µM of 2-meSATP spontaneously depolarized at later times during treatment,
somewhat consistent to findings in other studies.46 The significance and mechanism of these
ectopic events are unclear.
After observing that high concentration 2-meSATP stimulation of P2X4 receptors
resulted in robust immediate depolarizations, we questioned its effects on action potential
propagation in intact hearts. Somewhat to our surprise, we did not observe increased
arrhythmic activity in P2X4R OE hearts, even with high concentration 2-meSATP treatment.
In the WT intact hearts, however, we observed a significant increase in the number of
ectopic beats after high concentration 2-meSATP treatment. This may be consistent with
observations from others. Monophasic action potential recording in Langendorff-perfused
mouse hearts showed that high concentrations of ATP (10µM and 100µM) can induce
delayed after-depolarization (DAD) and ectopic APs, which can be blocked with 100µM
suramin or 30µM PPADS, but not with 10µM nifedipine.86 As nifedipine blocks the L-type
Ca2+ channel and in turn deplete SR Ca2+ storage, it was suggested that the ATP-induced
arrhythmic events likely involved Ca2+ influx via purinergic receptors. Ventricular tachycardia
(VT) was reported in 3 out of 7 spontaneous beating hearts and in 6 out of 7 hearts that were
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perfused with ATP for 20 minutes before being provoked with programmed electrical
stimulation.86 It is difficult to ascertain the severity of VT in this report given the relatively
loose definition of VT as three or more successive ectopic beats, but we did not observe any
sustained VT in our experiments. It is possible that 2-meSATP is less potent than ATP in
stimulating the subset of P2 receptors responsible for the proarrhythmic activities observed.
For example, 2-meSATP is a partial agonist of P2X4R receptors with an EC50 of 10 to
100µM, as opposed to ATP, which has an EC50 of 1 to 10µM.23 Given that the P2X4R is not
blocked by suramin or PPADS at the concentrations used to prevent ATP-induced
arrhythmias,23 combined with the fact that we did not observe increased propensity for
arrythmogenesis in our P2X4R OE hearts, it is unlikely that the P2X4 receptor played a role in
the arrhythmias elicited in the earlier report. ADP has also been shown to be
proarrhythmogenic to a lesser extent, while UTP and adenosine had no effect. This agonist
profile suggests that in the WT murine heart, P2Y1 and P2Y11 receptors may be involved in
the increased arrhythmogenesis, as they are linked to phospholipase C and cAMP pathways
that could increase mobilization of intracellular calcium.88 The P2Y11 receptor has also been
implicated to be responsible for ATP-induced inotropic increase in murine cardiac
myocytes.89 Phospholipase related IP3 production can activate IP3 receptors in the SR
membrane and nuclear envelope, which can modulate excitation contraction coupling by
sensitizing nearby ryanodine receptors, leading to positive inotropic but also pro-arrhythmic
effects.90 Since significant overexpression of a P2X channel in the P2X4R OE hearts did not
show an increased propensity to develop serious arrhythmias even at high concentrations of
the agonist, it is difficult to imagine how other P2X receptors would be proarrhythmogenic, as
they would operate similarly in terms of electrophysiology and most others are even faster
desensitizing or less Ca2+ permeant (except for P2X7 at high concentration agonist).
However, their involvement in the WT heart is not entirely ruled out, as localization is also
important and it is unknown if any of these channels are localized to the T-tubule
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invaginations. Staining for CaV1.2, the α1 subunit of cardiac dihydropyridine-sensitive Ltype Ca2+ channels, shows a characteristic striated pattern reflecting their localization in the
T-tubular system,91 which acts as the basis of calcium-induced calcium release. Staining for
P2X4 receptors in the P2X4R OE cardiomyocytes demonstrate clusters in the cell periphery
(Figure 4.1C in the following chapter), thus Ca2+ influx via this channel is unlikely to induce
spontaneous SR mobilization. Whether other P2X channels are juxtapositioned to calcium
release units on the SR remains to be studied. Overall, despite significant membrane
excitation due to P2X4R activation in the P2X4R OE single cardiomyocytes, we did not
observe increased propensity for these hearts to be more arrhythmic. Proarrhythmic
mechanisms active in single myocytes in many cases do not lead to a propagated response
in the intact tissue, because the current generated by a myocyte will leak away to its
neighbors without reaching the action potential threshold. The occurrence of a proarrhythmic
event will have to be synchronized in a sufficiently large group of myocytes in order to reach
the threshold for propagation away from that area. The transient nature of the P2X induced
depolarization also makes sustained arrhythmic activity unlikely in the whole heart.
We initially hypothesized that this transient depolarization due to P2X activation could
form a basis for the biphasic contractile phenotype seen in the whole heart. That is, a portion
of cardiomyocytes would initially have arrested APs and attenuated calcium transients that
reflect the initial depression in the whole heart, which, when followed by a subsequent
desensitization of the P2X current, would then lead to AP normalization and an enhanced
calcium transient in the later phase of enhanced contractions. Complementary to altering
agonist concentration, we hypothesized that increased myocyte surface P2X4R expression
would augment initial conductance and possibly prolong desensitization kinetics, leading to
an exaggerated biphasic response at a given concentration of agonist in the P2X4R OE
animals and ultimately to a left-shifted dose response curve as compared to WT. Our data,
however, did not indicate an obvious difference between WT and P2X4R OE hearts in terms
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of left ventricular pressure development in response to 2-meSATP. A biphasic contractile
response was observed in both, suggesting that depolarization at the cellular level is not
essential to the initial depressive phase of 2-meSATP induced biphasic response, as no
significant depolarization was seen in the WT cardiomyocytes. 2-meSATP, with the
hydrogen in position 2 of ATP replaced with a methylthio group, is thought to be more
resistant to nucleotidase breakdown and to lack coronary vasodilatory effects (adenosine
effect),50 however, some evidence suggest it is also prone to degradation by
ectonucleotidase enzymes.92 In the whole heart setting, the activity of these enzymes are
better preserved than in the isolated myocytes preparations, and thus the specificity of 2meSATP for P2X receptors in the whole heart is less clear and may explain the lack of
significant difference between WT and P2X4R OE heart. A small but significant difference
was observed between WT and P2X4R OE hearts at 1µM 2-meSATP, but additional study in
a global P2X4R KO line showed a response similar to WT. The persistence of the biphasic
response in the knockout animals further suggests that this response was not P2X4R specific.
The biphasic cardiac contractile response to purinergic agonism has been observed
in a few studies,39, 93, 94 however, this is the first observation in a working mouse heart model
looking at ventricular function with 2-meSATP as the agonist. The eventual enhancement of
cardiac function is consistent with previous observations,39, 49, 82 though the mechanism by
which this is achieved is still debated. It is encouraging that the biphasic contractile response
has previously been demonstrated in human atrial muscle strips,39 suggesting that the
cardiac functional responses of P2 agonism may be similar between rodents and human,
and that it is mediated directly by affecting force generating cells rather than indirectly
impacting other hemodynamic parameters such as HR. We did observe that with 100µM of
2-meSATP the heart rate progressively slowed down. This slowing could be a sign of agonist
breakdown and stimulation of adenosine receptors and/or other Gi coupled P2Y receptors,
as previous studies have indicated that ATP-induced slowed sinus pacemaker activity can
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be blocked by theophylline and pertussis toxin.95 Similar to previous work, in some cases an
initial HR acceleration was seen before it slowed, which could be related to release of
prostaglandins with purinergic activation.95, 96 The existence of multiple subtypes of P2
receptors in the native heart and additional release of soluble factors complicate
interpretation, but the crosstalks involved in these signaling pathways may be advantageous
as P2 agonist-induced positive inotropic effect did not entail a rate related increase in
myocardial oxygen consumption, as many current inotropes do.
The decrease in heart rate at the highest concentrations of 2-meSATP can partially
contribute to the higher pressure development. We also cannot rule out involvement of the
Frank-Starling mechanism in the later phase of the biphasic response. In the Frank-Starling
phenomena, stretched muscle fibers can generate larger forces, as it is thought that
stretching optimizes the overlap and interaction of myosin and actin filaments, and possibly
also increases the sensitivity of the myofilaments to Ca2+, which further augments force
development.97 In our experiment, the initial drop in pressure development can lead to
incomplete chamber emptying and a backlog of volume that accumulates in the ventricle
during diastole (bulging of the left atrium was sometimes visibly noticeable). This can
increase stretch on the myofibers and via the Frank-Starling mechanism induce greater
stroke volume on subsequent contractions. This, however, is unlikely the sole mechanism
involved as the enhancement can be sustained. While the interpretation of contractile
response in the whole heart is complicated by a number of considerations and not P2X4R
specific, we demonstrate that P2X4R induced cardiomyocyte depolarization is transient and
unlikely increases propensity for arrhythmia development.
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Chapter 4
P2X4 receptor-eNOS pathway in cardiac myocytes
d
as a novel protective mechanism in heart failure
4.1

INTRODUCTION
In previous experiments we have demonstrated that mice with P2X4R overexpression

are protected from heart failure progression in surgically induced and genetically altered
disease models. While an acute inotropic increase due to P2X activation can be explained
by its electrophysiological effects, other changes potentially responsible for more chronic
modulation of cardiac function are unknown. Since the P2X4R is calcium permeable and can
alter calcium handling inside a cell, a multitude of downstream effects could ensue. One such
possibility is the interaction with calcium-dependent nitric oxide synthases (NOS). P2X4R
mediated endothelial nitric oxide synthase (eNOS) activation has been shown previously in
endothelial cells, 56 with P2X4R deficient P2X4R-/- mice exhibiting aberrant endothelial cell flow
responses due to a blunting of flow mediated influx of Ca2+ and subsequent production of nitric
d
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oxide (NO). These deficits were rescued with adenoviral P2X4R gene transfer. Additionally, the
P2X4R-/- animals were shown to have higher blood pressure and to excrete smaller amounts of
NO products in their urine when compared to WT mice, and vessel dilation induced by acute
increases in blood flow was markedly suppressed.56
Cardiomyocytes also constitutively express eNOS and neuronal nitric oxide synthase
(nNOS),98 and regulation of these enzymes have significant impact on cardiac function.99, 100
The protective effect of eNOS and its stimulated second messenger, cGMP, against heart
failure development is widely confirmed.99, 101 We further examined a possible link between the
P2X4R and eNOS and considered the existence of a physical interaction. To test for functional
significance, NO and its downstream readouts were assayed and moreover, inhibition of eNOS
by pharmacology or genetic knockout was carried out in P2X4R OE transgenic mice subjected
to postinfarction and pressure overload HF.

4.2

MATERIALS AND METHODS

4.2.1 Determination of nitric oxide formation
NO formation inside isolated cardiomyocytes was first measured by real-time imaging
with diaminofluorescein-FM diacetate (DAF-FM DA, Molecular Probes, Eugene, OR).
Cardiomyocytes were loaded with 5µM of DAF-FM DA for 30min at 37°C before imaging on a
confocal microscope (Zeiss LSM510meta). Rod shaped striated myocytes were randomly
selected. Fluorescence was excited at 488nM and emission was filtered through a 525nm long
pass filter. Fluorescence intensities were quantified using MetaMorph (Molecular Devices, Inc,
Sunnyvale, CA). Myocytes were incubated with vehicle normal saline or 2-meSATP and
fluorescence determined at baseline and at each minute for 10 minutes.
In addition to time-series imaging with DAF-FM DA, we utilize a newly commercially
available NO-sensitive ﬂuorescent dye, 2-[4,5-bis[6-(2-ethoxy-2-oxoethoxy)-263

methylquinolin-8-ylamino]methyl]-6-hydroxy-3-oxo-3H-xanthen-9-yl}benzoic acid (FL2E) in
its copper complex form [Cu2(FL2E)] (Strem Chemicals, Inc., Newburyport, MA), to image
NO formation in living cardiac myocytes.102-104 The Cu2(FL2E) NO dye was prepared and
stored according to manufacturer instructions. Before experiments, myocytes were loaded
with 5 μM Cu2(FL2E) NO dye for 1 h in Tyrode's solution, then plated onto glass bottom
dishes for epifluorescence imaging with a Nikon Eclipse TE2000-S. Fluorescence was
captured with a 480/40 excitation ﬁlter and a 535/50 emission ﬁlter. Given the observation
that Cu2(FL2E) demonstrates increased fluorescence with light exposure alone, we
minimized data acquisition to pre- and 10 minutes post treatment, thus limiting view field
exposure to light. Random 40× ﬁelds rich in rod shaped striated myocytes were selected
and recorded with a CCD camera. Myocytes were incubated with buffer vehicle or 10 μM
2-meSATP (Sigma). 100 μM S-nitroso-N-acetyl-D,L-penicillamine (SNAP, Molecular Probes,
Life Technologies, Grand Island, NY), a NO donor, was used as a positive control. Fluorescence
intensities from individual rod shaped myocytes were quantiﬁed using ImageJ (NIH). Twenty to
sixty myocytes were counted from each plate before and after treatment for each mouse.

4.2.2

Immunoprecipitation, Immunoblotting, and Immunostaining
To test whether there is a physical interaction between P2X4R and eNOS, we

performed co-immunoprecipitation on cardiomyocyte lysates using mouse monoclonal eNOS
(BD Transduction; 1-3 µg) and rabbit polyclonal P2X4R (Alomone; 2µg). Cells were lysed in
HSE buffer (20mM HEPES, 150mM NaCl, 5mM EDTA, 1% Triton X-100 and protease
inhibitors (leupeptin, pepstatin, benzamidine and ARBSF), pH 7.4). Supernatants were
incubated at 4°C overnight with the indicated antibody and 15µL of prewashed Protein A/Gagarose. Following extensive washing, captured proteins were solubilized in sample buffer and
analyzed by immunoblot.
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For immunostaining of isolated cardiac myocytes to evaluate co-localization of P2X4R
and eNOS, cardiomyocytes were fixed with 4% paraformaldehyde in PBS for 20 minutes. Cells
were then cytospun onto slides for staining. Cardiomyocytes were permeabilized with 0.5%
Triton, and then blocked with 10% normal goat serum plus 3% BSA in PBS for 1 hour at room
temperature or 4°C overnight. Primary antibodies to eNOS and P2X4R (same as used in coimmunoprecipitation) were applied both at 1:150 dilution for 1 hour, followed by incubation with
secondary antibodies (goat-anti-mouse-FITC from Santa Cruz and goat-anti-rabbit-Texas Red
from Invitrogen) at 1:500 for 45 minutes at room temperature. Confocal fluorescence images
were acquired on a Carl Zeiss LSM 780 with 488nm and 561nm laser excitation using a 63X oil
lens (Carl Zeiss Microscopy, LLC, Thornwood, NY).
Antibodies specific for eNOS phosphorylation sites Ser1177 (Cell Signaling #9571) and
Thr495 (Cell Signaling #9574 and Millipore #04-811) were used to assess eNOS activation in
WT and P2X4R overexpression heart homogenates. Antibodies from Cell Signaling against all
three NOS isoforms: eNOS (#9572), nNOS (#4236), and inducible NOS (#2982) were also
used to examine expression differences.

4.2.3

Determination of cGMP levels
NO can lead to soluble guanylate cyclase production of cyclic guanosine

monophosphate (cGMP). We measured cGMP levels in left ventricular homogenates of P2X4R
OE and WT animals, following the manufacturer’s acetylated protocol (cGMP determination kit,
GE Healthcare). Isolated hearts were perfused with buffer, NO donor S-nitroso-Nacetylpenicillamine (SNAP, 100µM), or 2-meSATP (10µM) for 10 minutes in the working heart
mode before they were flash frozen in liquid nitrogen and stored at -80°C for further processing.

4.2.4

Biotin Switch for S-nitrosylated Proteins
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Heart tissues were obtained from P2X4R OE and WT animals (n=5 per group). 8 µm
thick tissue sections were subjected to biotin switch staining following the manufacturer’s
protocol (S-Nitrosylated Protein Detection Kit, Cayman Chemicals, Ann Arbor, MI). The biotin
switch method is based on the conversion of nitrosylated cysteines to biotinylated cysteines to
allow for detection of the NO-mediated modification of cysteine residues (addition of a
nitrosothiol). Slides were visualized on a confocal microscope (Zeiss LSM 510 meta) at 20X
magnification. Five 12-bit images of non-overlapping, tissue rich regions were acquired for each
slide. Images were segmented for positive staining areas, which were summed across five
images to produce a total area for each slide.

4.2.5

Surgical Models of Heart Failure
Animals with similar age (8-10 week old) and body weights were used. Mice were

anesthetized with ketamine (100mg/kg) and xylazine (10mg/kg) intraperitoneally. After
endotracheal intubation under a dissecting microscope at 37°C, the cannula was connected to
a small rodent ventilator (Hugo Sachs-Harvard Apparatus, Minivent Type 845, Holliston, MA) on
room air with a stroke volume of 0.3mL at a rate of 150 per minute. All animal procedures were
performed according to protocols approved by the University of Connecticut School of Medicine
Animal Use and Care Committee.

4.2.5.1 Left Anterior Descending (LAD) Ligation as a model of Myocardial Infarction
Permanent LAD ligation was performed to induce myocardial infarction (MI) related
heart failure as previously described.1 After anesthesia and intubation, a left intercostals
thoracotomy was performed. MI was produced by ligating the LAD with an 8-0 nylon suture
within 2mm below the edge of the left atrium, near the origin of the coronary artery.
Echocardiography was performed at 7 and 30 days after ligation to examine heart function in
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vivo. Cardiac function was also assessed ex vivo at 30 days after ligation, using the working
heart preparation (detailed in Section 3.2.4), in which equal loading conditions provide a
controlled environment to compare contractile performance, complementing
echocardiography measures.

4.2.5.2 Transverse aortic Constriction (TAC) as a model of Pressure Overload Heart
Failure
This model is distinct from ischemic injury leading to cardiac tissue death, but
represents a state of chronic afterload which the heart must work harder against to deliver
sufficient blood. The same opening steps as described above are followed. After left
intercostals thoracotomy, the thymus was carefully separated to expose the aortic issues
below it and surrounding tissues were carefully dissected to expose the aortic arch. TAC
was created by placing a 27-gauge needle on the transverse aorta between innominate and
left carotid arteries. A ligature of 7-0 Ethilon nylon suture was tied around the needle and the
aorta, after which the needle was removed. The increase in pressure proximal to the
constriction was confirmed by an increased Doppler jet velocity across the aortic banding
site. After euthanasia, the integrity of the banding was confirmed by inspection of the
surgical constriction and by visualization of differences in the caliber of the right and left
carotid arteries. All groups of mice had similar pressure gradients across their aortic band.
Echocardiography was performed at 7 days and 3 weeks after TAC.

4.2.6

Ablating eNOS activity in WT and P2X4R OE animals
The NOS inhibitor L-N5-(1-iminoethyl)ornithine hydrochloride (L-NIO; Sigma-Aldrich)

was administered via intraperitoneal injection at 40 mg/kg per day105 beginning at 3 days
before LAD or TAC until cardiac function determination at 7 days post surgery. Phosphate
buffer saline injections served as vehicle controls.
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Mice globally deficient in eNOS (B6.129P2-Nos3tm1Unc/J) were purchased from the
Jackson Laboratory (Bar Harbor, Maine) and bred with cardiac-specific P2X4R OE animals
to obtain P2X4R OE/eNOS KO mice.

4.2.7

Statistics
Statistical differences were mostly assessed by two-tailed Student's t-test. Two-way

ANOVA was used to test cGMP content differences across genotype and agonist
treatment. Data presented as mean ± SEM. We considered P values less than 0.05 to
be statistically signiﬁcant.

4. 3

RESULTS

4.3.1

P2X4R can induce NO formation and associates with eNOS
Since the P2X4R

receptor is calcium permeant, it
is possible that this receptor can
interact with and activate the
calcium-dependent endothelial
nitric oxide synthase (eNOS).
We investigated whether
stimulation of P2X receptors in
cardiac myocytes can lead to
formation of nitric oxide
molecules. Using the traditional

Figure 4.1
Example of change in DAF-FM
intensity at baseline vs. after exposure to P2X
agonist or vehicle. Note the declined intensity in
vehicle-treated cells due to photobleaching of
fluorescein. Bars indicate 10µm.

4-amino-5-methylamino-2’,7’difluorofluorescein (DAF-FM) diacetate dye for imaging nitric oxide (NO) in P2X4R OE
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cardiomyocytes, increased fluorescence was observed over baseline or vehicle-treatment
following 2-meSATP treatment (Figure 4.1). After 10 minutes, mean intensity with agonist
normalized to those with vehicle was 109.3±2.6% (n=33 cells for vehicle-treatment and n=43
cells for 2-meSATP, P<0.05). As evident from vehicle treatment, DAF-FM has the drawback
of photobleaching. Thus we repeated NO formation measurements with a newer NOsensitive fluorescent dye, Cu2(FL2E), which has been used to image NO formation in a

Figure 4.2 2-meSATP stimulated NO formation in P2X4R OE and WT cardiac
myocytes imaged with Cu2(FL2E) (a) Upper panel: Representative ﬂuorescence
images of Cu2(FL2E) loaded P2X4R OE cardiac ventricular myocytes before and after
SNAP or 2-meSATP treatment are shown. Lower ﬁgure: Quantification of
fluorescence change normalized to pre-treatment, *P<0.05 using paired t-test for
average ﬂuorescence intensity before and after treatment with SNAP (n=4 mice) or 2meSATP (n = 3 mice) from P2X4R OE animals. (b) Similar studies were carried out in
cardiac ventricular myocytes from WT animals (n = 2 mice). Upper and lower panels
show typical ﬂuorescence imaging and average fluorescence intensity for treatment with
SNAP and with 2-meSATP. *P<0.05 using paired t-test for SNAP or 2-meSATP
treatment. 20-80 cells were counted from each mouse for each treatment condition. Bars
indicate 10µm.
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variety of biological systems, including intact living cardiomyocytes. Cu2(FL2E) data
conﬁrmed NO formation following 2-meSATP stimulation in P2X4R OE myocytes (Figure
4.2a), as well as in WT myocytes (Figure 4.2b), with the former exhibiting greater NO
formation. Thus, using two structurally distinct dyes speciﬁc for NO, we demonstrate that
NO is increased within cardiac myocytes as a result of P2X receptor stimulation in both
P2X4R OE transgenic myocytes and WT cardiac myocytes.
In considering a mechanism for NO production following P2X4R stimulation, the P2X4
receptor was found to be present in eNOS immunoprecipitates obtained from cardiac
myocytes of both WT (Figure 4.3a) and P2X4R OE (Figure 4.3b) hearts. The specificity of
this physical interaction was supported by the absence of P2X4R in immunocomplexes
captured using an IgG matched control antibody. P2X4R and eNOS were both more
concentrated in sarcolemmal regions as assessed by immunostaining, and appear in close
proximity in specific areas along the sarcolemma (Figure 4.3c). Both proteins also showed
sarcolemmal staining in WT myocytes, although P2X4R staining was considerably fainter. The
increased NO production in P2X4R OE hearts was not due to an up-regulation of eNOS
protein expression or increased catalytic activity via phosphorylation of the serine 1177
residue (Figure 4.3d). There was no discernible band on immunoblots of WT and P2X4R OE
heart homogenates for phospho-eNOS Thr495, nor for iNOS. No difference was seen in
nNOS expression between the two genotypes (blot not shown). These data support the
activation of eNOS to produce NO following P2X4 channel activation.

70

d

Figure 4.3
P2X4R and eNOS are co-immunoprecipitated and can exist in close
proximity in cardiac ventricular myocytes (a) WT myocyte lysates were incubated
with anti-eNOS antibody or with non-speciﬁc IgG as control. The isolated complex was
probed with eNOS (top panel) and P2X4R (bottom panel) antibodies. P2X4R coimmunoprecipitated with eNOS antibody (lane 3) but not with control IgG (lane 2) and
self-precipitation by eNOS also served as a control. (b) Same experiment as in (a)
conducted in P2X4R OE transgenic myocytes. (c) Immunostaining of eNOS (green),
P2X4R (red), with merged image shown for a P2X4R OE cardiac myocyte. Bar
indicates 10µm. (d) Protein expression of eNOS did not differ between P2X4R OE and WT
hearts and neither did phosphorylation of Serine 1177 (p-S1177) on eNOS. Blots are shown
on the left and lane quantifications shown on the right (n = 5 each, P=0.32 for comparison of
eNOS expression as normalized to GAPDH, and P=0.66 for p-S1177 as normalized to
eNOS).
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4.3.2 P2X4R stimulated NO formation leads to downstream signaling
NO can induce further downstream signaling activity, likely through stimulation of
soluble guanylyl cyclase activation and 3′,5′-cyclic GMP (cGMP) formation, as well as
through the more recently discovered S-nitrosylation of cellular proteins. Indeed there was
an increased level of myocardial S-nitrosylation in P2X4R OE hearts as compared to WT
hearts (Figure 4.4a), in agreement with enhanced endogenous NO production. To assay
potential changes in cGMP, isolated hearts were perfused with buffer, 10µM 2-meSATP, or
100µM NO donor SNAP. SNAP caused a large increase in cGMP levels (buffer-perfused
P2X4R OE: 2.61±0.33 fmol/mg, n=5 vs. SNAP-perfused P2X4R OE: 5.61±0.40 fmol/mg, n=5,
P<0.05). The cGMP level was also higher in P2X4R OE hearts than in WT hearts after 2meSATP treatment, with similar drug responses in both genotypes (WT+buffer: 2.36±0.21
fmol/mg, n= 15; WT+2-meSATP: 2.83±0.26 fmol/mg, n=12; P2X4R OE+buffer:
2.76±0.19 fmol/mg, n=18; P2X4R OE+2-meSATP: 3.39±0.20 fmol/mg, n=16; twoway ANOVA p<0.05 for both P2X4R OE and 10µM 2-meSATP treatment with no

Figure 4.4 Increased cardiac protein S-nitrosylation and cGMP content in P2X4R OE
animals. (A) Typical examples of S-nitrosylated proteins in P2X4R OE and WT hearts (n = 5
for each) as determined using the biotin switch method. Bar indicates 30µm. Summed
positive areas from 5 images per heart produced one total area for each heart, with P2X4R
OE hearts showing a significantly greater area of positive staining compared to WT
(58563±9603 pixels for P2X4R OE vs. 31589±3771 pixels for WT, P=0.03). (B) Cardiac
tissue cGMP content is overall significantly higher in P2X4R OE hearts vs. WT and in hearts
that have been perfused with 10µM 2-meSATP vs. buffer (n= 15 for WT + buffer, n=12 for
WT + 2-meSATP, n=18 for P2X4R OE + buffer, and n=16 for P2X4R OE+ 2-meSATP).
72

significant interaction, summarized in Figure 4.4B). These data are consistent with
stimulation of the overexpressed cardiac P2X4R by endogenous extracellular ATP leading
to S-nitrosylation of proteins and cGMP formation in P2X4R OE hearts. Overall,
multiple lines of evidence point to P2X4 receptor-induced intra-myocyte NO production
with downstream functional consequences.

4.3.3

Cardiac P2X4R OE improved function after Pressure Overload
In addition to the previously demonstrated salutary effect of P2X4R OE against

ischemia cardiac injury, P2X4R OE mice were also protected against pressure overload
induced HF. The differences between P2X4R OE and WT manifested early. As early as 7
days after TAC, echocardiographic assessment demonstrated a significant difference
between WT and P2X4R OE mice, and better preserved function in P2X4R OE mice
continued to be evident at 3 weeks (Figure 4.5). 3 weeks after TAC, we observed moderate
left ventricular hypertrophy with reduced cardiac fractional shortening in most animals but no
overt HF or arrhythmias. P2X4R OE hearts also showed less fibrosis than WT hearts (n=16
for P2X4R OE, n=11 for WT, P<0.05 with both Picrosirius Red and Trichrome staining).
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Figure 4.5 P2X4R OE hearts have better cardiac function after transverse aortic
constriction. (A) P2X4R transgenic (Tg) mice (n=12) had better preserved fractional
shortening (FS) and greater ejection as marked by smaller left ventricular internal
diameter at end systole (LVIDs) compared to WT (n=11) at 7 days after TAC. (B)
Echocardiographic parameters again demonstrated higher FS and smaller LVIDs in
P2X4R Tg (n=16) than WT (n=18) 3 weeks after TAC. (C) Examining heart function ex
vivo showed greater +dP/dt and –dP/dt in Tg (n=18) than WT (n=18) hearts. γ P<0.05
P2X4R Tg vs. WT after 7 days of aortic banding; *P<0.05 WT subjected to TAC was lower
vs. sham WT (n=8), sham Tg (n=8 and 9) or Tg subjected to TAC; ** P<0.05 Tg subjected
to TAC was different from sham Tg or sham WT.
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4.3.4

Role of eNOS in mediating the protective effect of P2X4R in Heart Failure
In order to examine the role of eNOS in mediating P2X4R protection, we used a

pharmacological inhibitor of NOS, L-NIO, as well as gene ablation of eNOS in P2X4R OE
mice during heart failure (summarized in Figure 4.6). In one set of studies, we used the
ischemic heart failure model involving permanent ligation of the LAD coronary artery to
cause post-infarct heart failure. P2X4R OE led to a higher cardiac left ventricular fractional
shortening (FS) after infarction, but no infarct size difference was observed in mice of
various genotypes that were subjected to the ligation. Daily injection with L-NIO, which
has been used to demonstrate eNOS function in vivo,105 abrogated the improved
cardiac performance of P2X4R OE mice during ischemic HF when compared to WT,
as determined by both in vivo echocardiography and by ex vivo working heart
examination.
To further conﬁrm the role of eNOS in mediating the protective effect of the P2X4R
during HF, eNOS KO mice were crossed with P2X4R OE mice (P2X4R OE/eNOS KO).
KO of eNOS abrogated the protected phenotype conferred by the P2X4R OE genotype
in postinfarction HF. Both the improved + dP/dt and FS in P2X4R OE mice during HF were
lost in P2X4R OE/eNOS KO mice. To ascertain whether the protective effect of P2X4R–
eNOS is applicable to another form of HF, we tested the effects of P2X4R-induced protection
by pharmacological inhibition of eNOS on pressure overload HF. Pressure overload was
produced by aortic banding in P2X4R OE and WT mice. P2X4R OE hearts showed better
cardiac function as determined by echocardiography- derived FS after aortic banding. LNIO blocked the increased FS in these animals. KO of eNOS in Tg animals also
abrogated the improved FS in these Tg mice after aortic banding. These data provide
functional evidence for a P2X4R–eNOS interaction and support a key role of eNOS as a
mediator of cardiac P2X4R-induced protection in HF.
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Figure 4.6 eNOS activity inhibition abrogated the improved cardiac function by P2X4R overexpression in heart failure.
(A) Daily injection of L-NIO 3 days before and 7 days after LAD coronary artery ligation in P2X4R OE transgenic (Tg) mice (n=13)
resulted in a reduced FS compared with P2X4R OE mice not receiving drug (n=24). P2X4R OE mice receiving L-NIO had similar FS
as WT receiving the drug (n=21). (B) KO of eNOS in P2X4R OE mice blocked the improved +dP/dt and (C) FS by P2X4R
overexpression in postinfarct heart failure thirty days after LAD ligation. P2X4R OE mice (n=20) showed better +dP/dt compared with
P2X4R OE/eNOS KO (n=22), WT (n=9), or eNOS KO mice (n=21). Similarly, P2X4R OE mice (n=9) had greater FS than any other
genotype at 30d after ligation. WT (n=10), eNOS KO (n=14), P2X4R Tg/eNOS KO mice (n=12) did not differ in FS (ANOVA and posttest comparison). 3 weeks after TAC, (D) P2X4R Tg mice treated with vehicle subjected to TAC (n=22) had higher FS compared with
Tg animals that had received L-NIO injections (n=11); WT (n=11) and P2X4R Tg mice treated with L-NIO had similar FS. (E) P2X4R
OE mice (n=8) showed better FS compared with P2X4R Tg/eNOS KO (n=12) or eNOS KO mice (n=13). *P<0.05 vs any other group
on the same graph. P>0.05 among groups not marked.

4.4 DISCUSSION
In adult murine ventricular myocytes, the P2X agonist 2-meSATP induced a nonselective
cation current with reversal potential similar to that of the cloned P2X4 receptor.47 Transgenic
mice with cardiac-specific overexpression of the human P2X4R have previously been shown to
be protected from ischemic HF induced by LAD ligation and from a genetic model of dilated
cardiomyopathy from the overexpression of calsequestrin.1, 52 Previous evidence suggested that
activation of cardiac P2X receptors can elicit a cyclic AMP-independent increase in cardiac
contraction106 and as we discussed in the previous chapters, an electrophysiological basis exists
for increasing myocardial calcium transients and contraction.47, 107 However, the mechanisms by
which these ligand-gated channels protect against HF remain incompletely understood. Here we
demonstrated that eNOS is an effector in P2X4R-mediated cardioprotection.
Direct measurement of NO production was made in P2X4R OE and WT cardiac myocytes
after 2-meSATP stimulation. DAF-FM demonstrated a greater stimulated increase in NO level in
P2X4R OE over WT myocytes. The newer NO-sensitive dye Cu2(FL2E) corroborated the finding,
showing enhanced fluorescence in both WT and P2X4R OE cardiac myocytes after treatment
with the agonist, and a larger magnitude of change in the P2X4R OE myocytes. Furthermore,
the level of S-nitrosylated proteins and cGMP were higher in transgenic than in WT hearts,
consistent with a greater stimulation of endogenous NO production by the overexpressed P2X4
receptors in transgenic hearts. These findings provide functional evidence for the activation of
eNOS downstream of cardiac P2X4 receptors. The expression of eNOS in cardiac myocytes is
relatively low,108 but a modest increase in DAF fluorescence by a synthetic nitrone in murine
cardiac myocytes had a functionally significant impact in reversing contractile dysfunction,109
and our data showed a similar degree of increase in DAF fluorescence after P2X agonist
stimulation. The P2X4 receptor coimmunoprecipitated with eNOS in isolated cardiac myocyte
lysates from both P2X4R OE and WT animals. Co-immunostaining of P2X4R and eNOS in the
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sarcolemma of P2X4R OE transgenic cardiac myocytes further supports an interaction of these
two proteins. In considering other aspects of eNOS activation, phospho-eNOS Ser1177
normalized by total eNOS expression was unchanged in P2X4R OE vs. WT hearts.
Phosphorylation of Ser1177 increases eNOS catalytic activity, representing a mechanism of
eNOS activation different from that achieved by calmodulin binding.110 We postulate that the
mechanism of eNOS activation by P2X4 receptors is from Ca2+ increase and subsequent
calmodulin binding and may not involve Ser1177 phosphorylation. A close proximity between
P2X4 receptor and eNOS may prime for a confined domain of calcium to activate calmodulin
and subsequently eNOS. In endothelial cells where eNOS is more abundant, P2X4R has also
been implicated in stimulating eNOS,56 though the physical interaction between P2X4 receptor
and eNOS remains unstudied in the endothelium.
If the interaction of eNOS with cardiac P2X4 receptor is important in mediating the
protective effect seen in P2X4R OE animals, one would expect that the inhibition of eNOS could
block the cardiac P2X4 receptor protective effect, and we indeed found this. Either
pharmacological inhibition of eNOS by L-NIO or genetic KO of eNOS abrogated the HF
protective effect of cardiac P2X4R OE. Cardiac P2X4R OE ameliorated both ischemic and
pressure overload forms of HF. The cardioprotective effect of eNOS in ischemia/reperfusion
injury and in post-infarct HF has been demonstrated in eNOS-overexpressing transgenic
animals 111-113. Upregulating eNOS by H2S has also been shown to protect against pressure
overload HF.114 Although eNOS overexpression or upregulation is cardioprotective, eNOS KO
has been reported to increase, decrease, or cause no change in ischemia/reperfusion injury.111
The reason for these variable findings may have to do with the presence or absence of a
compensatory upregulation of inducible NOS in some of the eNOS KO mice. The eNOS-/- line
used in the present study, developed at the University of North Carolina and now available from
the Jackson Laboratory, has been shown to have upregulated iNOS.111 We did not observe a
more severe HF phenotype after infarction in these eNOS knockouts, consistent with their
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compensated phenotype. Nonetheless, protection provided by the P2X4R-eNOS interaction in
the P2X4R OE hearts was abrogated by eNOS knockout.
Additional caution was exercised when interpreting the data from L-NIO and eNOS KO
mice. While L-arginine analogues such as L-NIO are believed to be NOS inhibitors, they may
have other actions that secondarily affect remodeling after pressure overload or infarction as a
consequence of its inhibition of eNOS in the endothelium, such as inducing hypertension and
vasoconstriction. The eNOS KO animals exhibit mild hypertension and LV hypertrophy that
could in turn confound the salutary effect of cardiac myocyte-specific P2X4R OE. A more severe
HF could potentially result from pressure overload in eNOS KO animals, which may in turn
abrogate the beneficial effect of cardiac P2X4R OE. However, when the same eNOS KO mice
as used here were subjected to abdominal aortic banding, they did not show LV dilation when
compared with WT controls.115 In fact, ejection fraction was greater in eNOS KO than in WT
mice after abdominal banding. This apparent protection against abdominal banding may be
because of the compensatory upregulation of iNOS. However, in our postinfarct hearts, eNOS
KO was not protective because cardiac function was similarly depressed in both eNOS KO and
WT mice (Figure 4.6B).
The present data are consistent with previously reported protection by eNOS via the Ttype calcium channel in pressure overload HF.105 Although eNOS is cardioprotective, the
downstream effectors mediating eNOS activity are not entirely clear. Possible candidates
include cGMP, protein kinase G, and cellar protein S-nitrosylation.58, 116 Cardiac-speciﬁc
activation of eNOS may be more cardioprotective than an increased activity of global systemic
eNOS113 and intra-myocyte formation of nitric oxide may be more advantageous over nitric
oxide derived externally from a donor. Overall, new evidences support a P2X4R-eNOS
interaction and its functional significance in HF protection, pointing to a novel sarcolemmal
receptor-enzyme pathway in the heart.
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Chapter 5
Conclusionse

5.1

SUMMARY OF FINDINGS
P2X receptors are ligand-gated ion channels that regulate various physiological

processes and have emerged as promising therapeutic candidates for treatment of several
pathophysiological conditions such as heart failure. The transition from experimental validation
to clinical use necessitates a detailed mechanistic understanding of P2X mediated cardiac
effects, as well as potential side-effects of targeting these receptors. In the studies presented in
this dissertation, the downstream effects of activating these extracellular ATP responsive
receptors in cardiac myocytes were examined in a transgenic mouse model with cardiac specific
overexpression of the P2X4 subtype (P2X4R OE), as compared to wildtype (WT) and other
animals with relevant genetic modifications. We focused on electrophysiological consequences
that are of paramount importance to the cardiomyocyte and also uncovered a novel protein
interaction that has functional implications downstream of altered ion handling. First, in Chapter
2 we confirmed the hypothesis that cardiac P2X receptors can modulate the cardiac contractile
state by adjusting Na+ handling. Measurements of Na+-K+ ATPase (Ip) and Na+/Ca2+ exchanger
(INCX) currents in ventricular myocytes isolated from P2X4R OE mice indicated that the agonist,
2-methylthio adenosine-5-triphosphate (2-meSATP), increased peak Ip and the Ca2+ entry mode
of INCX. These results were supported by simulation and showed that 2-meSATP caused an
estimated [Na+]i increase of around 1mM. Inhibitors that preferentially oppose the Ca2+ entry
mode of NCX, KB-R7943 or a structurally different agent YM-244769, blunted the 2-meSATPinduced increase in cell shortening in P2X4R OE myocytes, suggesting that the Ca2+ entry mode
e

Part of this chapter exists in print: Yang R, Liang BT. “Cardiac P2X4 Receptors: Targets in Ischemia and Heart
Failure?” Circ Res. 111:397-401. 08/2012.
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of INCX participates in the P2X agonist-stimulated enhancement in contraction. In ventricular
myocytes from WT mice, despite a limited responsive subpopulation, P2X agonist also
increased INCX and KB-R7943 was able to inhibit contractile effects elicited by the agonist.
These data demonstrate a novel Na+ entry pathway through ligand-gated P2X4R in
cardiomyocytes that can subsequently modify contractile responses via the NCX.
In Chapter 3, we described experiments designed to better understand the potential
balance between arrhythmogenic effects versus anti-ischemic and heart failure protection
benefits of P2X4 receptor activation. Again utilizing cardiac specific P2X4R OE animals, we
found that activation of these receptors could lead to a brief period of membrane disturbance
lasting around half a minute, which can be mimicked with a computational model based on
known P2X4 current kinetics. This transient excitability of the P2X4R OE cardiomyocytes did not
translate to enhanced automaticity in the whole heart, and supports the notion of targeting P2X
subtypes for cardiac inotropic support with transient effects on excitability. Previous conflicting
results reflect measurements at different time points in the dynamic response and could also
result from different agonists and doses used in the studies. Low concentrations of P2X agonist
may be able to elicit an increase in contraction but not induce sufficient depolarization to cause
ectopic beats and diastolic calcium buildup, which were only observed at >10µM of ATP and
likely involve mechanisms other than P2X activation. Additionally, we unveiled a previously
unreported biphasic response to P2 agonism in the mouse heart, which was present in WT and
P2X4R KO animals as well. This substantiates the existence of multiple subtypes of P2
receptors in the native heart and emphasizes the importance of understanding the actions of
specific P2 subtypes.
Lastly, in Chapter 4 we reported a novel feature of the P2X4R in that the receptor is not
just an ion channel, but can associate with the enzyme endothelial nitric oxide synthase (eNOS).
In the cardiac myocyte, we showed that P2X4 receptor stimulation causes activation of eNOS,
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as demonstrated by increased NO formation with two structurally distinct NO-sensitive
ﬂuorescent dyes. Cardiac tissue from P2X4R OE mice also showed enhanced S-

Figure 5.1 Model of the mechanism of action of P2X receptors in cardiac
myocytes Ionic influx due to activation of the P2X4 receptor can lead to intracellular Na+ and
Ca2+ concentration changes, partly by affecting the NCX. A localized increase in Ca2+ near
eNOS can increase eNOS activity via calmodulin dependent activation. Some of the
increase in calcium is taken up by the sarcoplasmic reticulum (SR). NO production can lead to
stimulation of soluble guanylyl cyclase (sGC) with cyclic GMP accumulation as well as Snitrosylation of myocardial proteins. The NO pathway is known to exert a salutary
effect in heart failure and in ischemic injury.

nitrosylation and cGMP content. Blunting eNOS activity in P2X4R OE animals abrogated the
protective effect seen in these animals after surgically induced cardiac injury, consistent with a
functional significance for the P2X4R–eNOS pathway in mediating cardioprotection in heart
failure.
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Overall, we propose the model summarized in Figure 5.1, where Na+ entry via the P2X4
receptor enables further ion exchange through the NCX to enhance calcium retention inside the
cell. It is conceivable that P2X4 flux exerts a primarily localized control over calcium mediated
signaling with minimal or no effect on Ca2+ influx in the dyadic space. Diffusion of Ca2+ ions
allows them to reach and enter the SR for enhanced loading and inotropic enhancement. The
close physical distance between the P2X4R and eNOS primes NO production, which is beneficial
in the setting of ischemic injury and heart failure.

5.2

FUTURE DIRECTIONS
5.2.1

Additional P2X4R considerations for Regulating Cardiac Function

In addition to directly modulating cardiomyocyte ion handling in the classical excitation
contraction paradigm, the P2X4 receptor has been implicated in a number of physiological
processes that could indirectly modify cardiac function. Another possible mechanism by which
P2X4R may be of benefit in the diseased heart may lie with its mechanosensitive properties. It is
structurally similar to members of the mechanosensitive epithelial Na+ channel (ENaC) family,
and it has been shown that P2X4 receptor desensitization to repeated ATP stimulation is
prevented by applying shear stress to P2X4 expressing Xenopus oocytes.117 While this openchannel stabilizing mechanism is conceptually different from that of mechano-induced ATP
release and subsequent channel activation,56 they both support an important role for P2X4R in
cellular response to mechanical force. In the remodeling heart experiencing increased
mechanical stress, it is possible that enhanced P2X4R stimulation/opening may serve to
enhance cardiac contractility. Detailed examination of P2X4 activation and kinetics in myocytes
under mechanical loading may be feasible with recently developed techniques.118 Additionally,
the P2X4R has recently been demonstrated to exist on lysosome-related exocytotic vesicles.
Fusion of these vesicles to the plasma membrane leads to localized calcium increase that
further induces Ca2+-dependent vesicular fusion, promoting compound exocytosis.119 While the
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molecular exocytotic machinery in the heart is not well understood, it is tempting to speculate
that enhanced P2X4R signaling in ischemia or heart failure may augment cardiac release of
vesicular contents, which could contain cytokines and/or cardioprotective factors. Secretion of
natriuretic pepetides and vascular endothelial growth factor (VEGF) are known to be stimulated
under a number of conditions that involve hypoxia and mechanical stretch;120, 121 and P2X4Rmediated release of inflammatory mediators such as the known cardioprotectant brain-derived
neutrophic factor (BDNF)122 and P2X4R involvement in NLRP1 inflammasome signaling have
been demonstrated in spinal cord and peripheral nerve injuries.123 These scenarios are also
pertinent to myocardial injury, in which inflammatory responses are necessary for tissue repair
but need to be controlled and weighed against compensatory mechanisms to improve cardiac
function. The P2X4R receptor may be a novel participant in the regulation of this process.
In response to peripheral inflammatory challenges, mice lacking the P2X4R show a
complete absence of inflammatory prostaglandin E2 (PGE2) in tissue exudates and
consequently do not develop pain hypersensitivity due to the lack of PGE2 promotion of sensory
neuron hyperexcitability. PGE2 synthesis involves the activation of a multi-step enzymatic
cascade that includes cyclooxygenases (COXs), the targets of nonsteroidal anti-inflammatory
drugs. COX-2 inhibitors are used as anti-inflammatory and pain medication worldwide, though
they have been associated with elevated cardiovascular risk.124, 125 While a P2X4R antagonist
may be useful as a new therapy to treat neuropathic pain,126 our current data suggest that its
antagonism may be deleterious to those individuals under cardiac stress as well, including heart
failure. Modulating inflammatory responses has been considered a potential therapeutic
approach to preserve and recover heart function after myocardial infarction as well,127, 128 and
the role of the P2X4R in this setting remains to be clarified. A number of mouse models with cell
type specific knockout of the P2X4R are currently under development in our lab to permit
determination of the function of each component (cardiac myocytes, endothelial cells, and
monocytes) without confounding influence from other tissues and will together serve to
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illuminate a better systemic view of targeting this receptor in cardiac treatment. Recent data on
cardiac specific P2X4R knockouts showed worse outcome after ischemic and pressure overload
injuries,129 consistently with myocyte P2X4 receptors being cardioprotective in disease.

5.2.2

Understanding Human Polymorphisms in P2X receptors

Genetic variants in the human population can be quite informative about the
mechanisms of disease. In two Australian cohorts of healthy human subjects, containing 430
and 2874 subjects, a common allele with a non-synonymous single nucleotide (Tyr315 Cys)
polymorphic variant of the P2X4R gene was found to occur at a frequency of 1.1 and 1.4%
respectively. This loss-of-function genetic variant in humans is associated with increased blood
pulse pressure,57 consistent with the role of P2X4R in regulating vascular tone.56, 130 It has also
been found, along with another polymorphism in the P2X7R gene, to form a haplotype that
increases the risk of age-related macular degeneration in a cohort of 744 patients vs. 557
controls, likely due to impaired monocyte phagocytosis.131 These observations are consistent
with important roles for the P2X4R in processes that could impact cardiac function and
remodeling after injury and it would be of interest to test if this variant occurs with a higher
prevalence in heart failure. Complementary to the tissue specific knockout models, global and
tissue specific knockins of this polymorphic variant can serve as more relevant study models for
human disease.

5.2.3

Calcium and Nitrosative Signaling in Heart Failure

Electrophysiological remodeling in HF is complex and evolves over time as HF
progresses. In the early stages of HF, Ca2+ transients can be increased, likely due to elevated
intracellular Na+ concentration and relatively normal SR function at this time point.132 In the late
stages of HF, SERCA down-regulation and RyR leakiness depress SR storage, and along with
modifications of sarcolemmal channels and T-tubule disruption, contribute to dyssynchronous
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calcium release and impaired contraction.133 The cause and sequence of these changes remain
mostly unclear. Oxidative and nitrosative balance is also disturbed in heart failure. In healthy
tissue, superoxide is produced by xanthine oxidase, mitochondria, and NADPH oxidase, and
becomes rapidly buffered by glutathione and broken down by superoxide dismutase.109 The
diseased myocardium has elevated superoxide levels, along with a nitroso-redox imbalance, can
alter the function of a variety of excitation-contraction coupling proteins leading to contractile
dysfunction.133, 134 Dysfunctional NOS activity has been shown to lead to hyponitrosylation of the
RyR receptor, contributing to SR calcium leak and enhanced xanthine oxidase activity.135, 136
Antioxidant treatments have been shown to increase contractile function and promote
cardioprotection in failing hearts,137, 138 with success possibly incumbent on NO bioavailability.139
Therapies aimed at increasing endogenous NO bioavailability may also be beneficial.140 Whether
P2X dependent enhancement in contraction and NO production can function with significant late
alterations in the failing cardiomyocyte remain to be examined, as timing of therapy will likely
impact outcome. Early intervention may be necessary to observe optimal P2X4-mediated
protection.

5.2.4

Developing pharmacological tools and therapeutic drugs
In addition to P2X-mediated contractile enhancement and cardioprotection, recent

studies have also suggested differential roles played by various P2 receptors. P2Y11 receptors
may be largely responsible for ATP-induced inotropic increase, acting through cAMP and PLC
dependent pathways.89 The P2Y2 receptor has been suggested to mediate UTP-conferred
protection against myocardial damage after myocardial infarct,141 though the existence of this
receptor at the protein level has not been confirmed in the human heart.41 In P2Y2 knockout
mice, the UTP-conferred reduction in infarct size and improvement in cardiac function were
abrogated.141 Additional evidence supports stimulation of P2Y2 receptors as a protective
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mechanism to decrease angiotensin type 1 receptor density in cardiac fibroblasts through
inducible NOS-mediated S-nitrosylation of the p65 subunit of NF-kB, thus negatively regulating
angiotensin II-mediated inflammatory responses in the heart.142 The P2X7 receptor has also
been implicated in mediating effects of ischemic preconditioning and postconditioning, by
interacting with pannexin-I hemichannels to release multiple cardioprotectants in Landendorff ex
vivo rat hearts,143 which could be interesting given the functional haplotype with P2X4R.
However, another study exposing HL-1 atrial cells to hypoxic stress in culture detected an early
rise in ATP in culture, followed by increased release of cytoplasmic histone-associated DNAfragments, indicating cell death that was thought to be directly induced by P2Y2 and P2X7
receptor subtypes, whereas the P2Y4 receptor was thought to exert a protective effect.144
Addition of apyrase to degrade extracellular ATP, or adding GAP26 or 18aGA to inhibit
connexin hemichannels, also abolished hypoxic stress-associated apoptosis.144 The implications
of these results warrant further characterization and studies across different model systems.
Understanding the physiological roles of individual P2 receptors in the heart will be imperative
as interest grows in targeting purinergic receptor signaling in treating heart failure and ischemia.
The many permutations of subtype combinations and the paucity of highly selective agonists
and antagonists have made it difficult to ascertain the specific role of each P2 receptor in the
heart. Additional pharmacological tools, accompanied by genetic modifications and our
increasing ability to differentiate cells into specific lineages, may prove efficient at elucidating
cell type-specific molecular and cellular mechanisms.
Coronary heart disease and myocardial infarction are disorders of high prevalence and
incidence. According to the American Heart Association, a heart attack occurs every 34
seconds. Our results indicate that a small molecule drug stimulating or gene therapy-mediated
overexpression of the P2X4R in cardiac myocytes may represent a new therapy for both
ischemic and pressure overloaded HF. In light of the recent crystal structure obtained from
zebrafish P2X4R in the open state with ATP binding,145 new information on the conformational
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changes associated with P2X channel gating will enable guided design of new pharmacological
agents. Crystal structure and site-specific mutagenesis of P2X4R have elucidated the ATPbinding pocket, which resides at each pair of subunit interfaces in the trimeric channel. Four
positively charged lysine and arginine residues line the binding pocket for ATP, whose
phosphate groups mediate ligand specificity (ATP>ADP, AMP). Lys70 and Thr189 (Lys67 and
Thr186 in human homologue) are important in maintaining specificity over CTP, GTP, and
UTP.145 The human Tyr315Cys mutation that disrupts agonist binding is located within this
pocket. Additionally, the open state of the receptor leaves relatively large gaps that could be
filled in by lipids and allosteric modulators such as ivermectin.145 Detailed mechanisms of how
the open state can be stabilized by such modulators, and more intriguingly by mechanical
forces,117 would be of interest in future investigations. Additional challenges in drug design
include rapid adenine nucleotide degradation by extracellular nucleotidases and the negative
charges on nucleotides preventing oral absorption. Development of nucleotidase-resistant
ligands146 and prodrugs at P2X4 receptors with masked charges that can be restored after oral
absorption are additional goals for clinical application.

5.2.5 Computational Modeling of the Cardiac System
Quantitative modeling has served to enhance our understanding of AP generation and
excitation contraction coupling for more than half a century, reaching an advanced level allowing
accurate predictions for experimental studies. In our case, simulation results prompted studies
that helped to explain prior experimental disagreements and confirmed the notion that P2X
activation can achieve inotropic enhancement. While some improvements can be made to
incorporate more detailed descriptions of cardiac ion channels and proteins involved in EC
coupling, such as incorporating Markovian models of the Na+/K+ ATPase147 and SERCA148,
more interesting areas for future modeling investigations will involve channel modulation by cell
signaling pathways. Beta-adrenergic receptor and calcium/calmodulin-dependent protein kinase
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type II signaling pathway models in the heart have been under development,132, 149, 150 and nitric
oxide signaling would be another area of major interest. Models of myocardial energetics are
also being pursued,151, 152 which would serve as a crucial link to understand mismatched energy
supply and demand in heart failure and to understand the interactions between metabolism and
intracellular redox and nitrosative regulations.153 The actions of signaling proteins on their
molecular targets and the dynamics of the signaling pathway need to be incorporated, along
with spatial considerations and information transfer between organelles, for a holistic
understanding of the cellular system’s interactions. While significant challenges will need to be
overcome, tissue and organ level models are also useful for understanding AP propagation and
structure-related functional changes that occur in myocardial injury and failure, and may be
potentially useful in the clinical environment as tools to aid in the prevention, diagnosis and
treatment of cardiac diseases.154

5.3

FINAL THOUGHTS
This dissertation characterized the effects downstream of P2X4R activation in the

cardiomyocyte, and our results have pointed to a potentially rewarding translational outcome on
treatment of myocardial injury and failure. In addition to contributing to the purinergic field, the
mechanisms by which the P2X4R confer cardioprotection touch upon many important and active
areas in cardiobiology research, and continued progress in these fields, with synergistic
developments in experimental and computational arenas, will enhance our understanding of
and ability to manage and treat the complex disease that is heart failure.
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Appendix A

The human P2X4R gene is located on the q arm of chromosome 12 and the mouse gene is
located on chromosome 5. The gene contains 12 exons. Figure 1 demonstrates genetic
targeting for exon 2-5 deletion to generate genetic knockouts and Table 1 provides primer
sequences for genotyping.

Figure 1: P2X4R Gene Structure and Targeting for knockout generation

P2X4R OE mice
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aMHC Linker Forward
P2X4 Linker Reverse

GTC GAC TGA CTA ACT AGA AGC T
CTG AGC TGG TAT CAC ATA ATC C

P2X4floxed/floxed mice
Lox gtF
LoxgtR
Frt gtF
Frt gtR

TTG CGA TTC AGA CGC CAA CT
TCT ATT GCA GAC ATG CTA CC
TTC TGC CTT GGG TTC AAA TC
AGC CCC TTA CCC AGC TAC TC

Hprttm1(cre)Mnn/J mice
Transgene Forward
Transgene Reverse
Wildtype Forward
Wildtype Reverse

GCG GTC TGG CAG TAA AAA CTA TC
GTG AAA CAG CAT TGC TGT CAC TT
CAC AGT AGC TCT TCA GTC TGA TAA AA
TTT CTA TAG GAC TGA AAG ACT TGC TC

Table 1. Primer Sequences for genotyping
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